WO2022133097A1 - Synthesis of compounds that modulate use-dependent voltage-gated sodium channels - Google Patents
Synthesis of compounds that modulate use-dependent voltage-gated sodium channels Download PDFInfo
- Publication number
- WO2022133097A1 WO2022133097A1 PCT/US2021/063825 US2021063825W WO2022133097A1 WO 2022133097 A1 WO2022133097 A1 WO 2022133097A1 US 2021063825 W US2021063825 W US 2021063825W WO 2022133097 A1 WO2022133097 A1 WO 2022133097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- salt
- base
- reactor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 228
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 title description 3
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 title description 3
- 230000001419 dependent effect Effects 0.000 title description 3
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 106
- 230000008569 process Effects 0.000 claims abstract description 85
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 154
- 150000003839 salts Chemical class 0.000 claims description 73
- 238000006243 chemical reaction Methods 0.000 claims description 58
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 50
- 229940011051 isopropyl acetate Drugs 0.000 claims description 50
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 239000002904 solvent Substances 0.000 claims description 37
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 36
- -1 azide compound Chemical class 0.000 claims description 34
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical group CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 150000002941 palladium compounds Chemical class 0.000 claims description 16
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 150000001879 copper Chemical class 0.000 claims description 12
- 229940043279 diisopropylamine Drugs 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 10
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 10
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 claims description 8
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 7
- 150000002736 metal compounds Chemical class 0.000 claims description 7
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 150000001639 boron compounds Chemical class 0.000 claims description 6
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical group I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 5
- 238000010923 batch production Methods 0.000 claims description 5
- 229910000085 borane Inorganic materials 0.000 claims description 5
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 4
- QZUPHAGRBBOLTB-UHFFFAOYSA-N NSC 244302 Chemical group C=1C=CC=CC=1P(C(C)(C)C)C1=CC=CC=C1 QZUPHAGRBBOLTB-UHFFFAOYSA-N 0.000 claims description 3
- PVYPHUYXKVVURH-UHFFFAOYSA-N boron;2-methylpropan-2-amine Chemical group [B].CC(C)(C)N PVYPHUYXKVVURH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 238000005112 continuous flow technique Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 abstract description 2
- GCZUIPVRHLYYOG-BEFAXECRSA-N (2r,5s)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one Chemical compound O=C1N(C)CC[C@]11N[C@@H](C=2N=C(C=C(C)N=2)C=2C=CC(=CC=2)C(F)(F)F)CC1 GCZUIPVRHLYYOG-BEFAXECRSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 120
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 87
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 46
- 229910052757 nitrogen Inorganic materials 0.000 description 44
- 239000007787 solid Substances 0.000 description 36
- 238000003756 stirring Methods 0.000 description 36
- 239000010410 layer Substances 0.000 description 35
- 238000001914 filtration Methods 0.000 description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 32
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 30
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 25
- 238000007792 addition Methods 0.000 description 22
- 239000002002 slurry Substances 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 239000002585 base Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 125000001183 hydrocarbyl group Chemical group 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 11
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- NZFPEZSHJULZDR-IBGZPJMESA-N (3s)-3-amino-1-methyl-3-[3-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]prop-2-ynyl]pyrrolidin-2-one Chemical compound O=C1N(C)CC[C@@]1(N)CC#CC1=NC(C)=CC(C=2C=CC(=CC=2)C(F)(F)F)=N1 NZFPEZSHJULZDR-IBGZPJMESA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- GZUUTWXPONLFKU-UHFFFAOYSA-N 2-chloro-4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine Chemical compound ClC1=NC(C)=CC(C=2C=CC(=CC=2)C(F)(F)F)=N1 GZUUTWXPONLFKU-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- BOCIWLBENJQNBZ-VIFPVBQESA-N (3S)-1-methyl-2-oxo-3-prop-2-ynylpyrrolidine-3-carboxylic acid Chemical compound CN1C([C@](CC1)(C(=O)O)CC#C)=O BOCIWLBENJQNBZ-VIFPVBQESA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- GKFJEDWZQZKYHV-UHFFFAOYSA-N borane;2-methylpropan-2-amine Chemical compound B.CC(C)(C)N GKFJEDWZQZKYHV-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 238000001139 pH measurement Methods 0.000 description 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- HSYLTRBDKXZSGS-UHFFFAOYSA-N silver;bis(trifluoromethylsulfonyl)azanide Chemical compound [Ag+].FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F HSYLTRBDKXZSGS-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- VYOUBMJFTDMKRR-UHFFFAOYSA-L dichloropalladium;[2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound Cl[Pd]Cl.C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VYOUBMJFTDMKRR-UHFFFAOYSA-L 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- QUGUFLJIAFISSW-UHFFFAOYSA-N 1,4-difluorobenzene Chemical compound FC1=CC=C(F)C=C1 QUGUFLJIAFISSW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical group [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000000375 direct analysis in real time Methods 0.000 description 2
- 238000012063 dual-affinity re-targeting Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 2
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- PMWWAUBENRRILR-ZDUSSCGKSA-N tert-butyl n-[(3s)-1-methyl-2-oxo-3-prop-2-ynylpyrrolidin-3-yl]carbamate Chemical compound CN1CC[C@](CC#C)(NC(=O)OC(C)(C)C)C1=O PMWWAUBENRRILR-ZDUSSCGKSA-N 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- NBKZGRPRTQELKX-UHFFFAOYSA-N (2-methylpropan-2-yl)oxymethanone Chemical compound CC(C)(C)O[C]=O NBKZGRPRTQELKX-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-MRVPVSSYSA-N (2s)-2-amino-2-phenylethanol Chemical compound OC[C@@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 description 1
- HHOQVJBIPOKVRB-QMMMGPOBSA-N (3s)-3-amino-1-methyl-3-prop-2-ynylpyrrolidin-2-one Chemical compound CN1CC[C@@](N)(CC#C)C1=O HHOQVJBIPOKVRB-QMMMGPOBSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- BTLKROSJMNFSQZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyrimidine Chemical compound CC1=CC(Cl)=NC(Cl)=N1 BTLKROSJMNFSQZ-UHFFFAOYSA-N 0.000 description 1
- IYPICHLMDTYFPI-UHFFFAOYSA-N 2-methoxy-2-methylpropane;propan-2-ol Chemical compound CC(C)O.COC(C)(C)C IYPICHLMDTYFPI-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- QSVDFJNXDKTKTJ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indene Chemical compound C1CCCC2=C1CC=C2 QSVDFJNXDKTKTJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910004727 OSO3H Inorganic materials 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- UXDUCKXHQNXZNH-CRKQZGGQSA-N [(1S)-2-hydroxy-1-phenylethyl]azanium (3S)-1-methyl-2-oxo-3-prop-2-ynylpyrrolidine-3-carboxylate Chemical compound N[C@@H](C1=CC=CC=C1)CO.CN1C([C@](CC1)(C(=O)O)CC#C)=O UXDUCKXHQNXZNH-CRKQZGGQSA-N 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- JBFDZEJAJZJORO-UHFFFAOYSA-N bicyclo[4.1.0]hept-3-ene Chemical compound C1C=CCC2CC21 JBFDZEJAJZJORO-UHFFFAOYSA-N 0.000 description 1
- DCRRIOWFXXDTHV-UHFFFAOYSA-N bicyclo[4.2.0]oct-3-ene Chemical compound C1C=CCC2CCC21 DCRRIOWFXXDTHV-UHFFFAOYSA-N 0.000 description 1
- RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- LBVQLNOQOXKBSE-UHFFFAOYSA-N heptane;propan-2-yl acetate Chemical compound CCCCCCC.CC(C)OC(C)=O LBVQLNOQOXKBSE-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 238000005913 hydroamination reaction Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 238000010935 polish filtration Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- PAJRINVACHTMSQ-DEOSSOPVSA-N tert-butyl n-[(3s)-1-methyl-3-[3-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]prop-2-ynyl]-2-oxopyrrolidin-3-yl]carbamate Chemical compound O=C1N(C)CC[C@@]1(NC(=O)OC(C)(C)C)CC#CC1=NC(C)=CC(C=2C=CC(=CC=2)C(F)(F)F)=N1 PAJRINVACHTMSQ-DEOSSOPVSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Definitions
- (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-l,7- diazaspiro[4.4]nonan-6-one is described in Int. Pub. No. WO 2013/175205 as having utility in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.
- Certain synthetic methods to prepare (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)- phenyl]pyrimidin-2-yl]-l,7-diazaspiro[4.4]nonan-6-one are described in Int. Pub. Nos. WO 2013/175205 & WO 2019/075073. The contents of each of these patents are incorporated by reference in their entirety.
- the present invention provides processes for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III), in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
- the present invention further provides processes for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof, in the presence of a palladium compound and a copper salt and a base, thereby producing a compound of formula (VI):
- the present invention further provides processes for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III) in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV): reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (VI): and reducing the compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof
- the present invention further provides the compound of formula (V), or a salt thereof.
- the present invention further provides processes for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (VII) with an azide compound and an amine in the presence of /-butanol, thereby producing a compound of formula (VIII):
- the present invention further provides processes for purification of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
- the present invention further provides processes for preparing a compound of formula V, comprising reacting a compound of formula (VII) with an azide compound and an amine followed by treatment with a base: DETAILED DESCRIPTION OF THE INVENTION
- the present disclosure provides processes for preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III) in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
- the metal compound is a palladium compound,, such as palladium acetate.
- the phosphine that comprises an alkyl group is tert- butyldiphenylphosphine.
- the base is diisopropylethylamine.
- the compound of formula (II) is reacted with the compound of formula (HI) in the presence of a solvent, such as isopropanol.
- the chemical yield of the compound of formula (IV) is at least about 65% or at least about 70%.
- the compound of formula (II) is reacted with the compound of formula (HI) at a scale of at least 5 kg of the compound of formula (II) and at least 5 kg of the compound of formula (HI). In certain embodiments, the compound of formula (II) is reacted with the compound of formula (III) at a scale of at least 20 kg of the compound of formula (II) and at least 20 kg of the compound of formula (III). In certain embodiments, the compound of formula (II) is reacted with the compound of formula (HI) at a scale of at least 50 kg of the compound of formula (II) and at least 50 kg of the compound of formula (III).
- the present disclosure provides processes for preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof (such as a trifluoroacetate or hydrochloride salt), in the presence of a palladium compound, a metal salt and a base, thereby producing a compound of formula (VI): wherein the metal salt is not a silver salt.
- the compound of formula (V) is a trifluoroacetate salt. In certain embodiments, the compound of formula (V) is a hydrochloride salt. In certain embodiments, the compound of formula (V) is a not a salt (i.e., a flee base).
- the palladium compound is PdCh(dppf)-CH 2 Ch or PdCh(DPEphos).
- the metal salt is a copper salt, such as copper (I) iodide.
- the base is an organic base, such as diisopropylamine.
- the base is an inorganic base, such as potassium carbonate.
- the compound of formula (IV) is reacted with the compound of formula (V) in the presence of a solvent.
- the solvent comprises isopropyl acetate or acetonitrile.
- the chemical yield of the compound of formula (VI) is at least about 65%; at least about 70%; or at least about 75%.
- the compound of formula (IV) is reacted with the compound of formula (V) at a scale of at least 5 kg of the compound of formula (IV) and at least 5 kg of the compound of formula (V). In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (V) at a scale of at least 20 kg of the compound of formula (IV) and at least 20 kg of the compound of formula (V). In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (V) at a scale of at least 50 kg of the compound of formula (IV) and at least 50 kg of the compound of formula (V).
- the process further comprises reducing the compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof:
- the compound of formula (VI) is reduced to the compound of formula (I), or a pharmaceutically acceptable salt thereof in the presence of a boron compound.
- the boron compound is a borane, such as borane-tert- butyl amine complex.
- the present disclosure provides a compound of formula (V) or a salt thereof:
- die compound of formula (V) is a trifluoroacetate salt.
- the compound of formula (V) is a hydrochloride salt.
- the compound of formula (V) is a not a salt (i.e., a free base).
- the present disclosure provides a compound represented by the following structure:
- the present disclosure provides processes for preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, comprising converting a compound of formula (VII) to a compound of formula (VIII) in the presence of an azide compound and an amine in the presence of t-butanol:
- the azide compound is diphenylphosphoryl azide.
- the amine is N-methylmorpholine.
- the conversion of the compound of formula (VII) to the compound of formula (VIII) is carried out in the presence of a solvent.
- the solvent comprises toluene.
- the reaction is performed in a continuous flow process. In certain aspects, the reaction is performed in a batch process.
- the present disclosure provides processes for preparing a compound of formula (V), comprising reacting a compound of formula (VII) with an azide compound and an amine followed by treatment with a base:
- the azide compound is diphenylphosphoryl azide.
- the amine is N-methylmorpholine.
- the reaction is performed in a batch process.
- the conversion of the compound of formula (VII) to the compound of formula (V) is carried out in the presence of a solvent.
- the solvent comprises toluene.
- the base is aqueous sodium hydroxide.
- the conversion of the compound of formula (VII) to the compound of formula (VIII) is performed at a scale of at least 5 kg of the compound of formula (VII). In certain embodiments, die conversion of the compound of formula (VII) to the compound of formula (VIII) is performed at a scale of at least 20 kg of the compound of formula (VII). In certain embodiments, the conversion of the compound of formula (VII) to the compound of formula (VIU) is performed at a scale of at least 50 kg of the compound of formula (VII).
- the process further comprises reacting a compound of formula (IV) with the compound of formula (VIII) in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (IXa) or a salt thereof:
- the palladium compound is PdCh(DPEphos).
- the copper salt is copper (I) iodide.
- the base is an amine.
- the amine is diisopropylamine .
- the compound of formula (IV) is reacted with the compound of formula (VIII) in the presence of a solvent.
- the solvent comprises isopropyl acetate.
- the process further comprising reacting the compound of formula (IXa) with an acid, thereby producing a compound of formula (IX) or a salt thereof:
- the compound of formula (IXa) is reacted with the acid in the presence of a solvent.
- the solvent comprises acetonitrile.
- the acid is methanesulfonic acid .
- the process further comprising i) reacting a compound of formula (IV) with the compound of formula (VIII) in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (IXa) or a salt thereof; and ii) reacting a compound of formula (IXa) with an acid, thereby producing a compound of formula (IX) or a salt thereof wherein the compound of formula (IXa) is not isolated.
- the palladium catalyst is PdCh(DPEphos).
- the copper salt is copper(I) iodide.
- the base is diisopropylamine.
- the compound of formula (IV) is reacted with the compound of formula (VIII) in the presence of a solvent.
- the solvent comprises isopropyl acetate.
- the compound of formula (IXa) is reacted with the acid in the presence of a solvent.
- the solvent comprises isopropyl acetate and acetonitrile.
- tire process further comprises performing a cyclization reaction of the compound of formula (IX), or a salt thereof, in the presence of a metal salt to produce a compound of formula (VI):
- the metal salt is a copper salt, such as copper (I) iodide. In certain embodiments, the metal salt is not a silver salt. In certain embodiments, the compound of formula (IX) is a salicylate salt.
- the process further comprises reducing the compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof:
- the compound of formula (VI) is reduced to the compound of formula (I), or a pharmaceutically acceptable salt thereof in the presence of a boron compound.
- the boron compound is a borane.
- the borane is borane-tert-butyl amine complex.
- the present disclosure provides processes for the purification of a compound of formula (I): or a pharmaceutically acceptable salt thereof, comprising recrystallizing the compound of formula (I) or a pharmaceutically acceptable salt thereof in a solvent
- the compound of formula (I) is a hydrogen sulfate salt.
- the solvent comprises water and acetone.
- the solvent further comprises methyl t-butyl ether.
- the yield of the process is at least about 80%.
- the process provides the compound of formula (I) with a purity of at least about 99%; of at least about 99.5%; or at least about 99.9%.
- the purification of a compound of formula (I) is performed at a scale of at least 5 kg of the compound of formula (I). In certain embodiments, the purification of a compound of formula (I) is performed at a scale of at least 20 kg of the compound of formula (I). In certain embodiments, the purification of a compound of formula (I) is performed at a scale of at least 50 kg of the compound of formula (I).
- the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not.
- “optionally substituted alkyl” refers to the alkyl may be substituted as well as where the alkyl is not substituted.
- substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary' skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
- the term “optionally substituted” refers to the replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH 2 - O-alkyl, -OP(O)(O-alkyl) 2 or -CH 2 -OP(O)(O-alkyl) 2 .
- “optionally substituted” refers to the replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.
- alkyl refers to saturated aliphatic groups, including but not limited to C 1 -C 10 straight-chain alkyl groups or C 1 -C 10 branched-chain alkyl groups.
- the “alkyl” group refers to C 1 -C 6 straight-chain alkyl groups or C 1 -C 6 branched- chain alkyl groups.
- the “alkyl” group refers to C 1 -C4 straight-chain alkyl groups or C 1 -C 4 branched-chain alkyl groups.
- alkyl examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1 -pentyl, 2-pentyl, 3-pentyl, neo-pentyl, 1 -hexyl, 2-hexyl, 3-hexyl, 1 -heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1- octyl, 2-octyl, 3-octyl or 4-octyl and the like.
- the “alkyl” group may be optionally substituted.
- acyl is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.
- acylamino is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.
- acyloxy is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.
- alkoxy refers to an alkyl group having an oxygen attached thereto.
- Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
- alkoxyalkyl refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
- alkyl refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
- a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 - 30 for straight chains, C3-30 for branched chains), and more preferably 20 or fewer.
- alkyl as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2- trifluoroethyl, etc.
- C x -C y when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain.
- Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
- a C 1-6 alkyl group for example, contains from one to six carbon atoms in the chain.
- alkylamino refers to an amino group substituted with at least one alkyl group.
- alkylthio refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.
- amide refers to a group wherein R 9 and R 10 each independently represent a hydrogen or hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
- amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by wherein R 9 , R 10 , and R 10 ’ each independently represent a hydrogen or a hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
- aminoalkyl refers to an alkyl group substituted with an amino group.
- aralkyl refers to an alkyl group substituted with an aryl group.
- aryl as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
- the ring is a 5- to 7- membered ring, more preferably a 6-membered ring.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
- carboxylate is art-recognized and refers to a group wherein R 9 and R 10 independently represent hydrogen or a hydrocarbyl group.
- Carbocyclylalkyl refers to an alkyl group substituted with a carbocycle group.
- Carbocycle includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings.
- fused carbocycle refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings.
- an aromatic ring e.g., phenyl
- a saturated or unsaturated ring e.g., cyclohexane, cyclopentane, or cyclohexene.
- Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane.
- Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro- IH-indene and bicyclo[4.1.0]hept-3-ene.
- Carbocycles may be substituted at any one or more positions capable of bearing a hydrogen atom.
- carbonate is art-recognized and refers to a group -OCO 2 -.
- esters refers to a group -C(O)OR 9 wherein R 9 represents a hydrocarbyl group.
- ether refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O- heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
- halo and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
- heteroalkyl and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
- heteroaryl and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
- heteroaryl and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
- heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
- heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
- heterocyclyl refers to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
- heterocyclyl and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
- Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
- hydroxyalkyl refers to an alkyl group substituted with a hydroxy group.
- lower when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer.
- acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within tire aryl group are not counted when counting the carbon atoms in the alkyl substituent).
- polycyclyl refers to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”.
- Each of the rings of the polycycle can be substituted or unsubstituted.
- each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
- the term ‘‘sulfate” is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.
- sulfonamide is art-recognized and refers to the group represented by the general formulae wherein R 9 and R 10 independently represents hydrogen or hydrocarbyl.
- sulfoxide is art-recognized and refers to the group-S(O)-.
- sulfonate is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof.
- substituted refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
- Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphorate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety
- thioalkyl refers to an alkyl group substituted with a thiol group.
- thioester refers to a group -C(O)SR 9 or -SC(O)R 9 wherein R 9 represents a hydrocarbyl.
- thioether is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
- urea is art-recognized and may be represented by the general formula wherein R 9 and R 10 independently represent hydrogen or a hydrocarbyl.
- modulate includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.
- compositions, excipients, adjuvants, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Salt is used herein to refer to an acid addition salt or a basic addition salt.
- stereogenic center in their structure.
- This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30.
- the disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01/062726.
- reaction temperatures above 23 °C refer to jacket temperatures.
- 1 H and 13 C NMR spectra were recorded using Bruker AV-500, DRX- 500, and AV-400 MHz spectrometers, with 13 C NMR spectroscopic operating frequencies of 125, 125, and 100 MHz, respectively.
- ACN acetonitrile
- BOC tert-butoxy carbonyl
- CPME cyclopentyd methyl ether
- DCM dichloromethane
- DIPA diisopropylamine
- DIPEA diisopropylethylamine
- DMAP 4-dimethylaminopyridine
- DPPA diphenylphosphoryl azide
- DPEphos bis[(2-diphenylphosphino)phenyl] ether
- dppf 1,1*- bis(diphenylphosphino)ferrocene
- MsOH methanesulfonic acid
- MTBE methyl tert-butyl ether
- NMM N-methylmorpholine
- IPA isopropanol
- IPAc isopropyl acetate
- LDA lithium diisopropylamide
- Tf triflate
- TFA trifluoroacetic acid
- a reactor was charged with (4-(trifluoromethyl)phenyl)boronic acid (70 g), 2,4-dichloro-6- methylpyrimidine (66.1 g) and isopropanol (330 g), and the contents of the reactor were cooled to about 10 °C. With good stirring, DIPEA (143 g) and water (210 g) were charged, the contents of the reactor were aged at 10 °C for 15 - 30 min followed by sparging with nitrogen for 30 - 60 min.
- the contents of the reactor were cooled to about 10 °C, water (1052 g) was charged and the reaction mixture was aged for 5 - 10 h. Solids were isolated by filtration, washed with water ( 140 g) and dried to constant weight in vacuo at about 50 °C. A reactor was charged with the dried solids and methylcyclohexane (168 g) and with good stirring the contents of the reactor were heated to about 50 °C, aged for 2 - 8 h, cooled to about 0 °C and aged for 5 - 10 h.
- the contents of the reactor were maintained at 30 - 40 °C; the progress of the reaction was monitored by HPLC. Upon completion, the contents of the reactor were cooled to 20 - 25 °C. Solids were isolated by filtration, twice washed with CPME (43 g per wash) and dried to constant weight in vacuo at 40 °C to give 18.0 g (96%) of the title compound as its HC1 salt.
- the contents of the reactor were cooled to 20 - 25 °C and quenched into cold (0 - 5 °C) 2.5M aqueous NaOH solution (233 mL) over about 20 min.
- the mixture was aged for about 30 min, warmed to 20 - 25 °C and aged for about 15 h. Solids were removed by filtration, and the phases were separated.
- NaCl 250 g
- the solution was cooled to 0 - 5 °C and was aged for about 1 h. Solids were removed by filtration, washed with cold (0 - 5 °C) dichloromethane (333 g) and the phases were separated.
- the upper aqueous layer was twice extracted with dichloromethane (333 g per extraction) and the combined extracts were concentrated in vacuo to an oil, which was re-concentrated from dichloromethane (333 g).
- the oil was re-dissolved in dichloromethane (333 g), aged for about 1 h at 20 - 25 °C. Solids were removed by filtration, washed twice with dichloromethane (167 g per wash) and the combined filtrate and washes were concentrated in vacuo to an oil (36.9 g), determined by internal standard 1 H NMR analysis to contain 32.47 g (77%) of the free base form of the title product.
- the contents of the reactor were cooled to 20 °C and isopropyl acetate (52.2 g) was charged.
- the organic layer was treated with water (60 g) for about 10 min, and the layers were separated.
- the organic solution was treated twice for about 15 min (50 mL per treatment) with an aqueous solution prepared from NaCl (60 g), concentrated NH*0H solution (20 mL), L-cysteine (2 g) and water (200 mL).
- the organic phase was washed with brine (50 mL), concentrated to about 30 mL in vacuo and re-concentrated twice from isopropyl acetate (43.5 g per concentration) to a volume of about 30 mL each time.
- a reactor was charged with one-half of the product solution (27.63 g) from Example 3 Procedure B (containing 7.12 g of the product (theory)) and acetonitrile (22.1 g). After briefly sparging the solution with nitrogen, a solution of tert-butylamine - borane (1.31 g) in acetonitrile (14.2 g) was charged slowly over about 5 min; the progress of the reaction, performed at 25 °C, was monitored by UPLC. After about 5 h, the contents of the reactor were cooled to 0 - 5 °C and 5M aqueous HC1 solution (28 mL) was slowly charged under a nitrogen sweep.
- the contents of the reactor were warmed to 25 °C and aged for about 15 min.
- the contents of the reactor were transferred to a 500 mL Erlenmeyer flask.
- the reactor was rinsed forward into the flask with acetonitrile (8.4 g).
- a 50 wt% aqueous K 3 PO 4 solution (71 mL) was slowly added with good stirring over about 30 min and the mixture was aged for about 30 min.
- the layers were separated and the aqueous layer was back-extracted with acetonitrile (11.1 g).
- Acetonitrile (25.3 g) was added and the mixture was re-concentrated to about 18 mL. After three repetitions of this re-concentration process (KF ⁇ 1%), solids were removed by filtration and the filter cake was washed with acetonitrile (5.6 g). The KF of the filtrate (21 .93 g) was adjusted to 2.7% by charging water (0.57 g). The solution was warmed to about 50 °C, a 7.5M aqueous solution of H2SO4 (2.44 mL) was added dropwise over about 10 min and the resulting slurry was aged at about 50 °C for about 1 h.
- a reactor was charged with one-half of the product solution (27.17 g) from Example 3 Procedure B (containing 7.12 g of the product (theory)).
- the acetonitrile solution was stirred three times for about 15 min with an aqueous NH 4 OH - brine solution (35 mL per treatment; the solution was prepared by adding concentrated NH 4 OH solution (10 mL) into brine (100 mL)).
- the organic solution was stirred twice for about 30 min with an aqueous NH 4 OH - brine - L-cysteine solution (35 mL per treatment; the solution was prepared by adding concentrated NH 4 OH solution ( 10 mL) and L-cysteine (1.22 g) into brine (100 mL)).
- the contents of the reactor were cooled to 0 - 5 °C and a 50 wt% aqueous K 3 PO 4 solution (71 mL) was slowly- added with good stirring over about 15 min.
- the contents of the reactor were warmed to about 10 °C and aged for about 15 min.
- the layers were separated and the aqueous layer was back-extracted with acetonitrile (11.1 g).
- the combined organic layers were washed with brine (28 mL) and concentrated in vacuo to a volume of about 18 mL.
- the slurry was cooled to 0 - 5 °C and aged for about 1 h. Solids were isolated by filtration, washed with cold (0 - 5 °C) acetonitrile - MTBE (1 : 1 v/v, 14 mL) and cold (0 - 5 °C) MTBE (10.4 g) and dried to constant weight in vacuo at 40 °C to yield 3.69 g (41% from 2-chloro-4-methyl-6-[4- (trifluoromethyl)phenyl]pyrimidine) of the title product; 98 % area purity.
- the solution was warmed to about 50 °C, a 7.5M aqueous solution of H2SO4 (0.57 kg) was added dropwise over about 1 h and the resulting slurry was aged at about 50 °C for about 1 h .
- the slurry was cooled to about 20 °C over 45 min, isopropanol (0.93 kg) was charged and the slurry was aged for about 12 h.
- the slurry was cooled to 0- 5 °C over about 45 min and aged for about 2.25 h.
- the slurry was aged for about 1 h, cooled to about 25 °C over about 1 h, aged for about 18 h, cooled to 0 - 5 °C over about 1 h and aged for about 3 h. Solids were isolated by filtration, twice washed with cold (0 - 5 °C) acetone (0.33 kg per wash) and dried to constant weight in vacuo at 50 °C to give 433 g (83%) of the title compound; 99.9 % area.
- a reactor was charged with l-methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (75.2 kg activity) and isopropanol (413.3 kg) and the mixture was heated to 50 °C with good stirring.
- the resulting solution was aged for about 20 min at 50 °C, slowly cooled to about 41 °C and was seeded (100 g).
- a reactor was charged with (.S)-2-hydroxy-l-phenylethan-l-aminium (S)-l-methyl-2-oxo-3- (prop-2-yn-l-yl)pyrrolidine-3 -carboxylate (1:1, 47.2 kg activity) and water (141 kg), and the contents of the reactor were cooled to 0 - 5 °C with good stirring.
- Concentrated HC1 solution (16.48 kg) was added slowly to about pH 1.43, the contents of the reactor were warmed to 20 °C and aged for about 2 h. After charging NaCl (23.6 kg), the solution was heated to about 45 °C and was extracted three times with 2-methylTHF (201.5 kg per extraction).
- Procedure A batch process Under an inert atmosphere of nitrogen a reactor was charged with (S)-l-methyl-2-oxo-3- (prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (750 g), N-methylmorpholine (435 g) and toluene (9.14 kg). With good stirring, the contents of the reactor were heated to 77 - 80 °C followed by slow addition of DPPA (1173 g) over about 15 min; the charging vessel and line were rinsed forward into the reactor with toluene (653 g). The progress of the reaction was monitored by GC.
- the organic phase was treated twice for about 15 min with 2M aqueous NH 4 OH solution (4.5 L per treatment), treated twice for about 15 min with IM aqueous HC1 solution (7.5 L per treatment) and dried over anhydrous MgSO* (750 g) for about 1 h. Solids were removed by filtration and washed twice with dichloromethane (2 kg per wash). The filtrate was concentrated in vacuo to a volume of about 1.5 L and MTBE - heptane (1:2 v/v, 3.75 L) was added over about 20 min at 20 - 25 °C with good stirring. The slurry was cooled to 0 - 5 °C and was aged for about 2 h. Solids were isolated by filtration, washed twice with heptane (1.0 kg per wash) and dried to constant weight in vacuo at 30 °C to give 690 g (66%) of the title compound; 98.0 % area purity.
- Feed 1 Solution (S)-l-methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (24.34 kg), /V-methylmorpholine (27.1 kg) and r-BuOH (99.6 kg); this feed solution was maintained at 25- 35 °C during the run
- Feed 2 Solution DPPA (46.02 kg) and toluene (218.1 kg); this feed solution was maintained at 5 - 25 °C during the run
- each unit contains 6 pipes, each of about 1 m in length o up flow: three 1 inch diameter pipes o down flow: three 1 /4 inch diameter pipes
- Part A a reactor was charged with 2-chloro-4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidine (20.0 kg) and tert-butyl (S)-(l-methyl-2-oxo-3-(prop-2- yn-l-yl)pyrrolidin-3-yl)carbamate (20.1 kg). After three vacuum / nitrogen break cycles, the reactor was charged with isopropyl acetate (44 kg) and the contents of the reactor were stirred at 20 °C. After charging diisopropylamine (8.2 kg) the container and transfer line were rinsed forward into the reactor with isopropyl acetate (4.4 kg).
- the reactor was charged with a slurry composed of dichloro[bis[2- (diphenylphosphino)phenyl
- Part B To the solution prepared in Part A at 20 °C was charged acetonitrile (56.9 kg). With good stirring, methansulfonic acid (21.1 kg) was added over about 15 min while controlling the reaction temperature at ⁇ 26 °C. Following the addition, the container and transfer line were rinsed forward into the reactor with acetonitrile (7.9 kg) and the contents of the reactor were heated to 60 - 70 °C (target: 65 °C); the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to about 45 °C and purified water (179.3 kg) was charged over about 90 min while maintaining a reaction temperature of 45 - 50 °C.
- the contents of the reactor were cooled to 18 - 25 °C and aged for about 15 min.
- the layers were separated and the lower aqueous layer was basified (pH >12) with 50 wt% aqueous K 3 PO 4 solution (33.60 kg) over about 30 min while maintaining a reaction temperature of 20 - 25 °C.
- Isopropyl acetate (62.6 kg) was charged and the contents of the reactor were stirred for about 10 min.
- the layers were separated and the lower aqueous layer was back extracted with isopropyl acetate (41.1 kg).
- the combined organic layers were concentrated in vacuo to a volume of about 108 L.
- Isopropyl acetate (156.3 kg) was charged and the solution was concentrated in vacuo to a volume of about 72 L.
- Part C The solution prepared in Part B was polish filtered.
- the reactor which contained the solution and the transfer line were rinsed forward with isopropyl acetate (10 kg).
- the contents of the reactor were warmed to 30 - 40 °C (target: 35 °C) with good stirring.
- a solution of salicylic acid ( 12.2 kg) in isopropyl acetate (63.5 kg) was added over about 110 min while maintaining a reaction temperature of 32 - 36 °C.
- the contents of the reactor were aged at 30 - 40 °C (target: 35 °C) for about 3 h, cooled to 24 - 26 °C (target: 25 °C) over about 2 h, cooled to -5 to -15 °C (target: -10 °C) over about 80 min and aged for about 35 min.
- Solids were isolated by filtration, twice washed with cold (0 - 5 °C) MTBE - ACN (1:1 v/v, 59 L per wash), dried on the filter (jacket temperature: 60 °C) under suction while applying a stream of warm nitrogen (60 °C) for about 14 h followed by further drying on the filter under suction for about 33 h to give 28.9 kg (75%) of the title compound; purify: 97.6 % area; chiral purify: 99.8 % area.
- Part A A reactor was charged with 1,10-phenanthroline (465 mg) and MeOH (15 mL). With good stirring at ambient temperature, a solution of AgNTf 2 (1.00 g) in water (15 mL) was added. After aging for about 15 min, solids were isolated by filtration, washed with MeOH and dried to constant weight in vacuo at ambient temperature to give 920 mg (78%) of Ag(phen) 1.4 NTf 2 .
- 1 H and 19 F NMR spectra (d 6 -DMSO) using 1,4-difluorobenzene as an internal standard indicated a mol ratio of AgNTf 2 : 1,10- phenanthroline 1:1.4.
- Part B A reactor was charged with a solution of (5)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pynolidin-2-one (1 .10 g) in isopropanol (4.5 mL). Following addition of Ag(phen)i.4NTf 2 (161 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 20 h. UPLC analysis showed that 96 % area of the title compound was present in the solution.
- Part A A reactor was charged with 1,10-phenanthroline (2.00 g) and MeOH (70 mL). With good stirring at ambient temperature, a solution of AgOTf (2.85 g) in water (70 mL) was added. After aging for about 15 min, solids were isolated by filtration, washed with MeOH and dried to constant weight in vacuo at ambient temperature to give 3.35 g (>100%) of Ag(phen) 2.5 OTf.
- 1 H and 19 F NMR spectra (d 6 -DMSO) using 1 ,4-difluorobenzene as an internal standard indicated a mol ratio of AgOTf : 1,10- phenanthroline 1 :2.5.
- Part B a reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidm-2-one, salicylic acid salt (1:1) (6 g) and dichloromethane (60 mL). With good stirring, 20 wt% aqueous K 3 PO 4 solution was charged. Following salt dissolution and a pH measurement of the aqueous layer ( ⁇ 12), the layers were separated and the upper aqueous layer was back extracted with dichloromethane.
- a reactor was charged with (5)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (1.35 g) and acetonitrile (5 mL).
- salicylic acid salt (1:1) (1.35 g)
- acetonitrile 5 mL
- the resulting solution was heated to about 80 °C and aged for about 23 h.
- UPLC analysis showed that 42 % area of the title compound was present in the solution.
- Part A a reactor was charged with 2-chloro-4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidine (10.0 g) and tert-butyl (S)-(l-methyl-2-oxo-3-(prop-2-yn- l-yl)pyrrolidin-3-yl)carbamate (9.99 g), diisopropylamine (4.08 g), dichloro[bis[2- (diphenylphosphino)phenyl]ether]palladium (II) (66 mg), Cui (35 mg) and isopropyl acetate (26.1 g).
- Part B To the solution prepared in Part A at 20 °C was charged acetonitrile (22.1 g) and methansulfonic acid (6.96 g) and the contents of the reactor were heated to 65 °C; the progress of the reaction was monitored by UPLC. Upon completion, water (70 mL) was charged and the contents of the reactor were cooled to about 20 °C. The layers were separated and the lower aqueous layer was basified (pH ⁇ 12) with 50 wt% aqueous K 3 PO 4 solution (52 mL). Isopropyl acetate (24.4 g) was charged, the layers were separated and the lower aqueous layer was back extracted with isopropyl acetate (12.2 g).
- Part C The solution prepared in Part B was sparged with nitrogen for about 15 min. After charging Cui (267 mg), the contents of the reactor were sparged with nitrogen for about 15 min then heated to 75 °C; the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to 40 °C and aged for about 16 h. Solids w-ere isolated by filtration, washed twice with isopropyl acetate (19.1g per wash) and dried to constant weight in vacuo at 40 °C to give 7.4g (68%) of the tide compound; purity-: 99.9 % area.
- Part A a reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (28.55 kg) and dichloromethane (310.0 kg). With good stirring, the reaction temperature was adjusted to 15 - 25 °C (target: 18 °C) and 20 wt% aqueous K 3 PO 4 solution (210.85 kg) was charged over about 25 min while maintaining a reaction temperature of ⁇ 30 °C.
- the solution prepared in Part A at 15 - 25 °C (target: 20 °C) was subjected to four vacuum / nitrogen break cycles. After charging a slurry of CuI (434 g) in isopropyl acetate (1.0 kg) to the reactor, the container and charging line were rinsed forward into the reactor with isopropyl acetate (0.6 kg). After four vacuum / nitrogen break cycles and sparging the solution with nitrogen for about 30 min, the contents of the reactor were heated to 70 - 80 °C (target: 75 °C); the progress of the reaction was monitored by UPLC.
- the contents of the reactor were cooled to 37 - 43 °C (target: 40 °C) over about 3.5 h; the progress of the crystallization was monitored by ReactIR. Upon completion, the contents of the reactor were aged at 37 - 40 °C (target: 40 °C) for about 2 h.
- Solids were isolated by filtration, washed twice with isopropyl acetate (29.8 kg per wash), dried on the filter for about 1 h under a stream of nitrogen, dried on the filter (jacket temperature: 40 °C) while applying a stream of warm nitrogen (40 °C) for about 15 h followed by further drying on the filter under suction for about 15 h to give 13.1 kg (62%) of the title compound; purity: 99.9 % area.
- Example 12 Preparation of (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1) Under an inert atmosphere of nitrogen a reactor was charged with (S)-7-methyl-2-(4-methyl- 6-(4-(trifluoromethy l)phenyl)pyriniidin-2-y 1)- 1 ,7-diazaspiro [4 ,4]non- 1 -en-6-one ( 13.0 kg) and acetonitrile (71.7 kg) and with good stirring the contents of the reactor were adjusted to 15 - 25 °C (target: 19 °C).
- a solution of tert-butylamine - borane complex (2.4 kg) in acetonitrile (25.7 kg) was charged over 35 - 40 min while maintaining a reaction temperature of ⁇ 20 °C.
- the vessel and charging line were rinsed forward into the reactor with acetonitrile (10.3 kg); the progress of the reaction was monitored by UPLC.
- the contents of the reactor were cooled to 10 - 15 °C (target: 12 °C) and 5M aqueous HC1 solution (55.55 kg) was added over about 1 h while maintaining a reaction temperature of ⁇ 20 °C.
- the contents of the reactor were aged for about 30 min.
- Isopropanol (10.2 kg) was charged over about 25 min, the slurry was aged for about 12 h, cooled to 0 - 5 °C over about 2.25 h and aged for about 2 h. Solids were isolated by filtration, washed with cold (0 - 5 °C) MTBE - ACN (1:1 v/v, 20 kg), cold (0 - 5 °C) MTBE (19.3 kg), dried on the filter while applying a stream of nitrogen for about 90 min, dried on the filter (jacket temperature: 40 °C) while applying a stream of warm nitrogen (40 °C) for about 12 h followed by further drying on the filter under suction for about 17 h to give 11.95 kg (73%) of the title compound; purity: 98.6 % area.
- the contents of the reactor were warmed to 38 - 43 °C (target: 40 °C) over about 1.5 h, aged for about 2 h, cooled to 8 - 14 °C (target: 10 °C) over about 4.5 h and aged for about 12 h.
- Solids were isolated by filtration, washed twice with cold (0 - 5 °C) MTBE - acetone (1 : 1 v/v, 21.5 kg per wash), dried on the filter while applying a stream of nitrogen for about 1 h, dried on the filter (jacket temperature: 60 °C) while applying a stream of warm nitrogen (60 °C) for about 12 h followed by further drying on the filter under suction for about 33.5 h to give 10.14 kg (85%) of the title compound; purity: 99.9 % area.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The disclosure provides processes for preparing spiro derivatives, in particular (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7- diazaspiro[4.4]nonan-6-one, as well as intermediates for use in said processes.
Description
SYNTHESIS OF COMPOUNDS THAT MODULATE USE- DEPENDENT VOLTAGE-GATED SODIUM CHANNELS
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application No. 63/126,873, filed December 17, 2020, the contents of which are incorporated herein by reference in their entirety.
BACKGROUND OF THE INVENTION
(2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-l,7- diazaspiro[4.4]nonan-6-one:
is described in Int. Pub. No. WO 2013/175205 as having utility in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels. Certain synthetic methods to prepare (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)- phenyl]pyrimidin-2-yl]-l,7-diazaspiro[4.4]nonan-6-one are described in Int. Pub. Nos. WO 2013/175205 & WO 2019/075073. The contents of each of these patents are incorporated by reference in their entirety.
However, there is a need for the development of alternative processes for the preparation of such spiro derivatives, which are capable of practical application to large scale manufacture.
SUMMARY OF THE INVENTION
The present invention provides processes for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III), in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
The present invention further provides processes for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof, in the presence of a palladium compound and a copper salt and a base, thereby producing a compound of formula (VI):
The present invention further provides processes for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III) in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (VI):
and reducing the compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof
The present invention further provides processes for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (VII) with an azide compound and an amine in the presence of /-butanol, thereby producing a compound of formula (VIII):
(VII) (VIII)
The present invention further provides processes for purification of the compound of formula (I),
or a pharmaceutically acceptable salt thereof.
The present invention further provides processes for preparing a compound of formula V, comprising reacting a compound of formula (VII) with an azide compound and an amine followed by treatment with a base:
DETAILED DESCRIPTION OF THE INVENTION
In certain aspects, the present disclosure provides processes for preparing a compound of formula (I):
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III) in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
In certain embodiments, the metal compound is a palladium compound,, such as palladium acetate.
In certain embodiments, the phosphine that comprises an alkyl group is tert- butyldiphenylphosphine.
In certain embodiments, the base is diisopropylethylamine.
In certain embodiments, the compound of formula (II) is reacted with the compound of formula (HI) in the presence of a solvent, such as isopropanol.
In certain embodiments, the chemical yield of the compound of formula (IV) is at least about 65% or at least about 70%.
In certain embodiments, the compound of formula (II) is reacted with the compound of formula (HI) at a scale of at least 5 kg of the compound of formula (II) and at least 5 kg of the compound of formula (HI). In certain embodiments, the compound of formula (II) is reacted with the compound of formula (III) at a scale of at least 20 kg of the compound of formula (II) and at least 20 kg of the compound of formula (III). In certain embodiments, the compound of formula (II) is reacted with the compound of formula (HI) at a scale of at least 50 kg of the compound of formula (II) and at least 50 kg of the compound of formula (III).
In certain aspects, the present disclosure provides processes for preparing a compound of formula (I):
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof (such as a trifluoroacetate or hydrochloride salt), in the presence of a palladium compound, a metal salt and a base, thereby producing a compound of formula (VI):
wherein the metal salt is not a silver salt.
In certain embodiments, the compound of formula (V) is a trifluoroacetate salt. In certain embodiments, the compound of formula (V) is a hydrochloride salt. In certain embodiments, the compound of formula (V) is a not a salt (i.e., a flee base).
In certain embodiments, the palladium compound is PdCh(dppf)-CH2Ch or PdCh(DPEphos).
In certain embodiments, the metal salt is a copper salt, such as copper (I) iodide.
In certain embodiments, the base is an organic base, such as diisopropylamine.
In certain embodiments, the base is an inorganic base, such as potassium carbonate.
In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (V) in the presence of a solvent. In certain embodiments, the solvent comprises isopropyl acetate or acetonitrile.
In certain embodiments, the chemical yield of the compound of formula (VI) is at least about 65%; at least about 70%; or at least about 75%.
In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (V) at a scale of at least 5 kg of the compound of formula (IV) and at least 5 kg of
the compound of formula (V). In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (V) at a scale of at least 20 kg of the compound of formula (IV) and at least 20 kg of the compound of formula (V). In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (V) at a scale of at least 50 kg of the compound of formula (IV) and at least 50 kg of the compound of formula (V).
In certain aspects, the process further comprises reducing the compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof:
In certain embodiments, the compound of formula (VI) is reduced to the compound of formula (I), or a pharmaceutically acceptable salt thereof in the presence of a boron compound. In certain embodiments, the boron compound is a borane, such as borane-tert- butyl amine complex.
In certain embodiments, die compound of formula (V) is a trifluoroacetate salt. In certain embodiments, the compound of formula (V) is a hydrochloride salt. In other embodiments, the compound of formula (V) is a not a salt (i.e., a free base).
In certain aspects, the present disclosure provides a compound represented by the following structure:
In certain aspects, the present disclosure provides processes for preparing a compound of formula (I):
or a pharmaceutically acceptable salt thereof, comprising converting a compound of formula (VII) to a compound of formula (VIII) in the presence of an azide compound and an amine in the presence of t-butanol:
(VII) (VIII)
In certain embodiments, the azide compound is diphenylphosphoryl azide.
In certain embodiments, the amine is N-methylmorpholine.
In certain embodiments, the conversion of the compound of formula (VII) to the compound of formula (VIII) is carried out in the presence of a solvent. In certain embodiments, the solvent comprises toluene.
In certain embodiments, the reaction is performed in a continuous flow process. In certain aspects, the reaction is performed in a batch process.
In certain aspects, the present disclosure provides processes for preparing a compound of formula (V), comprising reacting a compound of formula (VII) with an azide compound and an amine followed by treatment with a base:
In certain embodiments, the azide compound is diphenylphosphoryl azide.
In certain embodiments, the amine is N-methylmorpholine.
In certain embodiments, the reaction is performed in a batch process.
In certain embodiments, the conversion of the compound of formula (VII) to the compound of formula (V) is carried out in the presence of a solvent. In certain embodiments, the solvent comprises toluene.
In certain embodiments, the base is aqueous sodium hydroxide.
In certain embodiments, the conversion of the compound of formula (VII) to the compound of formula (VIII) is performed at a scale of at least 5 kg of the compound of formula (VII). In certain embodiments, die conversion of the compound of formula (VII) to the compound of formula (VIII) is performed at a scale of at least 20 kg of the compound of formula (VII). In certain embodiments, the conversion of the compound of formula (VII) to the compound of formula (VIU) is performed at a scale of at least 50 kg of the compound of formula (VII).
In certain embodiments, the process further comprises reacting a compound of formula (IV) with the compound of formula (VIII) in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (IXa) or a salt thereof:
In certain embodiments, the palladium compound is PdCh(DPEphos).
In certain embodiments, the copper salt is copper (I) iodide.
In certain embodiments, the base is an amine. In certain embodiments, the amine is diisopropylamine .
In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (VIII) in the presence of a solvent. In certain embodiments, the solvent comprises isopropyl acetate.
In certain embodiments, the process further comprising reacting the compound of formula (IXa) with an acid, thereby producing a compound of formula (IX) or a salt thereof:
In certain embodiments, the compound of formula (IXa) is reacted with the acid in the presence of a solvent. In certain embodiments, the solvent comprises acetonitrile.
In certain embodiments, the acid is methanesulfonic acid .
In certain embodiments, the process further comprising i) reacting a compound of formula (IV) with the compound of formula (VIII) in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (IXa) or a salt thereof; and ii) reacting a compound of formula (IXa) with an acid, thereby producing a compound of formula (IX) or a salt thereof
wherein the compound of formula (IXa) is not isolated.
In certain embodiments, the palladium catalyst is PdCh(DPEphos).
In certain embodiments, the copper salt is copper(I) iodide.
In certain embodiments, the base is diisopropylamine.
In certain embodiments, the compound of formula (IV) is reacted with the compound of formula (VIII) in the presence of a solvent. In certain embodiments, the solvent comprises isopropyl acetate.
In certain embodiments, the compound of formula (IXa) is reacted with the acid in the presence of a solvent. In certain embodiments, the solvent comprises isopropyl acetate and acetonitrile.
In certain embodiments, tire process further comprises performing a cyclization reaction of the compound of formula (IX), or a salt thereof, in the presence of a metal salt to produce a compound of formula (VI):
In certain embodiments, the metal salt is a copper salt, such as copper (I) iodide. In certain embodiments, the metal salt is not a silver salt.
In certain embodiments, the compound of formula (IX) is a salicylate salt.
In certain embodiments, the process further comprises reducing the compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof:
In certain embodiments, the compound of formula (VI) is reduced to the compound of formula (I), or a pharmaceutically acceptable salt thereof in the presence of a boron compound. In certain embodiments, the boron compound is a borane. In certain embodiments, the borane is borane-tert-butyl amine complex.
In certain aspects, the present disclosure provides processes for the purification of a compound of formula (I):
or a pharmaceutically acceptable salt thereof, comprising recrystallizing the compound of formula (I) or a pharmaceutically acceptable salt thereof in a solvent
In certain embodiments, the compound of formula (I) is a hydrogen sulfate salt.
In certain embodiments, the solvent comprises water and acetone.
In certain embodiments, the solvent further comprises methyl t-butyl ether.
In certain embodiments, the yield of the process is at least about 80%.
In certain embodiments, the process provides the compound of formula (I) with a purity of at least about 99%; of at least about 99.5%; or at least about 99.9%.
In certain embodiments, the purification of a compound of formula (I) is performed at a scale of at least 5 kg of the compound of formula (I). In certain embodiments, the purification of a compound of formula (I) is performed at a scale of at least 20 kg of the
compound of formula (I). In certain embodiments, the purification of a compound of formula (I) is performed at a scale of at least 50 kg of the compound of formula (I).
Definitions
Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry', cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well-known and commonly used in the art.
The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N.Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, W. H. Freeman & Co., N.Y. (1999); and Gilbert et al., “Developmental Biology', 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).
Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, C.A. (1985).
All of the above, and any other publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.
As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not. For example, “optionally substituted alkyl” refers to the alkyl may be substituted as well as where the alkyl is not substituted.
It is understood that substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary' skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the
art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
As used herein, the term “optionally substituted” refers to the replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2- O-alkyl, -OP(O)(O-alkyl)2or -CH2-OP(O)(O-alkyl)2. Preferably, “optionally substituted” refers to the replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.
As used herein, the term “alkyl” refers to saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkyl groups or C1-C10 branched-chain alkyl groups. Preferably, the “alkyl” group refers to C1-C6 straight-chain alkyl groups or C1-C6 branched- chain alkyl groups. Most preferably, the “alkyl” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkyl groups. Examples of “alkyl” include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1 -pentyl, 2-pentyl, 3-pentyl, neo-pentyl, 1 -hexyl, 2-hexyl, 3-hexyl, 1 -heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1- octyl, 2-octyl, 3-octyl or 4-octyl and the like. The “alkyl” group may be optionally substituted.
The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.
The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.
The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.
The term “alkoxy” refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
The term ‘‘alkyl” refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1- 30 for straight chains, C3-30 for branched chains), and more preferably 20 or fewer.
Moreover, the term “alkyl” as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2- trifluoroethyl, etc.
The term “Cx-Cy" or “Cx-Cy”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. A C1-6alkyl group, for example, contains from one to six carbon atoms in the chain.
The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.
The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.
The term “amide”, as used herein, refers to a group
wherein R9 and R10 each independently represent a hydrogen or hydrocarbyl group, or R9 and R10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
wherein R9, R10, and R10’ each independently represent a hydrogen or a hydrocarbyl group, or R9 and R10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group.
The term “aralkyl’', as used herein, refers to an alkyl group substituted with an aryl group.
The term “aryl” as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7- membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
The term “carbamate” is art-recognized and refers to a group
wherein R9 and R10 independently represent hydrogen or a hydrocarbyl group.
The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.
The term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro- IH-indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.
The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.
The term “carbonate” is art-recognized and refers to a group -OCO2-.
The term “carboxy”, as used herein, refers to a group represented by the formula -CO2H.
The term “ester”, as used herein, refers to a group -C(O)OR9 wherein R9 represents a hydrocarbyl group.
The term “ether”, as used herein, refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O- heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.
The terms “heterocyclyl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more
preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms " heterocyclyl” and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a =0 or =S substituent, and typically has at least one carbonhydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a =0 substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.
The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer. A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within tire aryl group are not counted when counting the carbon atoms in the alkyl substituent).
The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
The term ‘‘sulfate” is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.
The term “sulfonamide” is art-recognized and refers to the group represented by the general formulae
wherein R9 and R10 independently represents hydrogen or hydrocarbyl.
The term “sulfoxide” is art-recognized and refers to the group-S(O)-.
The term “sulfonate” is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof.
The term “sulfone” is art-recognized and refers to the group -S(O)i-.
The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphorate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group.
The term “thioester”, as used herein, refers to a group -C(O)SR9 or -SC(O)R9 wherein R9 represents a hydrocarbyl.
The term “thioether”, as used herein, is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
The term “urea” is art-recognized and may be represented by the general formula
wherein R9 and R10 independently represent hydrogen or a hydrocarbyl.
The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.
The phrase “pharmaceutically acceptable” is art-recognized. In certain embodiments, the term includes compositions, excipients, adjuvants, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
“Salt” is used herein to refer to an acid addition salt or a basic addition salt.
Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01/062726.
Furthermore, certain compounds which contain alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both mixture and separate individual isomers.
Some of the compounds may also exist in tautomeric forms. Such forms, although not explicitly indicated in the formulae described herein, are intended to be included within the scope of the present disclosure.
EXAMPLES
In order that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope.
Exenrelarv Materials and Methods
Unless otherwise stated, reactions were periformed in jacketed glass-lined reactors under a nitrogen atmosphere. All solvents and reagents were used as received from commercial sources, unless otherwise noted. Reaction temperatures above 23 °C refer to jacket temperatures. 1H and 13C NMR spectra were recorded using Bruker AV-500, DRX- 500, and AV-400 MHz spectrometers, with 13C NMR spectroscopic operating frequencies of 125, 125, and 100 MHz, respectively. Chemical shifts (δ) are reported in parts per million (ppm) relative to the residual protonated solvent: CDCb signal (δ = 7.26 for 1H NMR; δ = 77.2 for 13C NMR), C6D6 signal (δ = 7.16 for 1H NMR; δ = 128.1 for 13C NMR), DMSO-d6 (δ = 2.50 for lH NMR; δ = 39.5 for 13C NMR). Data for lH NMR spectra are reported as follows: chemical shift, multiplicity, coupling constants (Hz), and number of hydrogen atoms. Data for 13C NMR spectra are reported in terms of chemical shift. The following abbreviations are used to describe the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; quint = quintet; m = multiplet; br = broad. Melting points (MP) are uncorrected and were recorded using an Electrothermal® capillary melting point apparatus. IR spectra were recorded on a Jasco FTIR-4100 spectrometer with an ATR attachment; the selected signals are reported in cm-1. HRMS (DART) was performed using a Thermo Fisher Scientific Exactive Plus spectrometer equipped with an lonSense ID-CUBE DART source. X-ray crystallographic data were collected using a Bruker SMART CCD-based diffractometer equipped with a low-temperature apparatus operated at 100 K.
Abbreviations:
Abbreviations: ACN, acetonitrile; BOC, tert-butoxy carbonyl; CPME, cyclopentyd methyl ether; DCM, dichloromethane; DIPA, diisopropylamine; DIPEA, diisopropylethylamine; DMAP, 4-dimethylaminopyridine; DPPA, diphenylphosphoryl azide; DPEphos, bis[(2-diphenylphosphino)phenyl] ether; dppf, 1,1*- bis(diphenylphosphino)ferrocene; MsOH, methanesulfonic acid; MTBE, methyl tert-butyl
ether; NMM, N-methylmorpholine; IPA, isopropanol; IPAc, isopropyl acetate; LDA, lithium diisopropylamide; phen, phenanthroline; Tf, triflate; TFA, trifluoroacetic acid; THF, tetrahydrofuran.
A reactor was charged with (4-(trifluoromethyl)phenyl)boronic acid (70 g), 2,4-dichloro-6- methylpyrimidine (66.1 g) and isopropanol (330 g), and the contents of the reactor were cooled to about 10 °C. With good stirring, DIPEA (143 g) and water (210 g) were charged, the contents of the reactor were aged at 10 °C for 15 - 30 min followed by sparging with nitrogen for 30 - 60 min. Under an inert atmosphere of nitrogen, Pd(OAc)2 (828 mg) and tert-butyldiphenylphosphine (1.8 g) were charged and the reaction was aged for 15 - 20 h while monitoring its progress by HPLC (completion: 100(% area boronic area / (% area boronic acid + % area product) ≤ 50). The contents of the reactor were warmed to about 25 °C, aged for about 24 h, slowly warmed to about 55 °C and aged for 10 - 20 h while continuing to monitor reaction progress by HPLC (completion: 100(% area boronic area / (% area boronic acid + % area product) < 1.5). Upon completion, the contents of the reactor were cooled to about 10 °C, water (1052 g) was charged and the reaction mixture was aged for 5 - 10 h. Solids were isolated by filtration, washed with water ( 140 g) and dried to constant weight in vacuo at about 50 °C. A reactor was charged with the dried solids and methylcyclohexane (168 g) and with good stirring the contents of the reactor were heated to about 50 °C, aged for 2 - 8 h, cooled to about 0 °C and aged for 5 - 10 h. Solids were isolated by filtration, washed with the mother liquor, twice washed with methylcyclohexane (56 g per wash) and dried to constant weight in vacuo at 55 °C to give 74.1 g (74%) of the title product; 99.2 % area purity.
Example 2: Preparation of (S)-3-amino-l-methyl-3-(prop-2-yn-l-yl)pyrroIidin-2-one
Into a reactor containing TFA (100 mL) cooled to 0 - 5 °C was charged terr-butyl (*S)-(1 - methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidin-3-yl)carbamate (50.0 g) in portions over about 1 h with good stirring. Following the charge, the contents of the reactor were wanned to 25 °C and aged for about 1 h. Following addition of toluene (34.8 g) the solution was concentrated tn vacuo to about 50 mL and re-concentrated three times from toluene (43.5 g per concentration) to give a viscous oil. After charging MTBE (148 g) and aging at ambient temperature with good stirring, solids were isolated by filtration, washed twice with MTBE (74 g per wash) and dried to constant weight in vacuo at 40 °C to give 49.62 g (94%) of the title compound as its TFA salt.
Into a reactor containing 3M HC1 in cyclopentyl methyl ether (89.5 g) was charged tert-butyl (S)-(l-methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidin-3-yl)caibamate (25.0 g) in portions.
Following the charge, the contents of the reactor were maintained at 30 - 40 °C; the progress of the reaction was monitored by HPLC. Upon completion, the contents of the reactor were cooled to 20 - 25 °C. Solids were isolated by filtration, twice washed with CPME (43 g per wash) and dried to constant weight in vacuo at 40 °C to give 18.0 g (96%) of the title compound as its HC1 salt.
Under an inert atmosphere of nitrogen, a reactor was charged with (S)-l-methyl-2-oxo-3- (prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (50.0 g activity), N-methylmorpholine (29.0 g) and anhydrous toluene (564 g). With good stirring, the contents of the reactor were heated to 77 - 80 °C and DPPA (78.3 g) was added over about 30 min; the charging line was rinsed forward into the reactor using toluene (43.3 g). The progress of the reaction was monitored
by GC. After about 3 h, the contents of the reactor were cooled to 20 - 25 °C and quenched into cold (0 - 5 °C) 2.5M aqueous NaOH solution (233 mL) over about 20 min. The mixture was aged for about 30 min, warmed to 20 - 25 °C and aged for about 15 h. Solids were removed by filtration, and the phases were separated. To the lower aqueous phase was added NaCl (250 g) with good stirring. The solution was cooled to 0 - 5 °C and was aged for about 1 h. Solids were removed by filtration, washed with cold (0 - 5 °C) dichloromethane (333 g) and the phases were separated. The upper aqueous layer was twice extracted with dichloromethane (333 g per extraction) and the combined extracts were concentrated in vacuo to an oil, which was re-concentrated from dichloromethane (333 g). The oil was re-dissolved in dichloromethane (333 g), aged for about 1 h at 20 - 25 °C. Solids were removed by filtration, washed twice with dichloromethane (167 g per wash) and the combined filtrate and washes were concentrated in vacuo to an oil (36.9 g), determined by internal standard 1H NMR analysis to contain 32.47 g (77%) of the free base form of the title product.
With good stirring, the oil was re-dissolved in dichloromethane (492 g), the solution was cooled to 8 - 12 °C, 3M HC1 in cyclopentyl methyl ether (95.8 g) was added over about 15 min and the slurry was aged for about 1 h. Solids were isolated by filtration, washed with dichloromethane (246 g), twice slimy washed with acetonitrile (146 g per wash) and dried to constant weight at ambient temperature to give 37.3 g (70% assay corrected yield) of the title compound as its HC1 salt.
Example 3: Preparation of (S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]non-l-en-6-one
Procedure A
A reactor was charged with (S)-3-amino-l-methyl-3-(prop-2-yn-l-yl)pyrrolidin-2-one (2.0 g), 2-chloro-4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine (3.58 g), diisopropylamine (1.46 g), dichloro[bis[2-(diphenylphosphino)phenyl]ether]palladium (II) (24 mg), Cui (12.5 mg) and isopropyl acetate (8.7 g). After sparging the solution with nitrogen, the contents of the reactor were heated to 75 - 80 °C; the progress of the reaction was monitored by UPLC. After about 48 h, 77 % area of the title product was present in the solution.
A reactor was charged with (S)-3-amino-l-methyl-3-(prop-2-yn-l-yl)pyrrolidin-2-one trifluoroacetic acid salt (1:1; 11.0 g), 2-chloro-4-methyl-6-[4- (trifluoromethyl)phenyl]pyrimidine (10.0 g), diisopropylamine (9.36 g) and acetonitrile (23.7 g). With good stirring at ambient temperature, the mixture was sparged with nitrogen for about 3 min. After charging PdCb(dppf) - CH2C12 (152 mg) and Cui (70 mg) and nitrogen
sparging for an additional 3 min, the contents of the reactor were heated to about 80 °C; the progress of the reaction was monitored by UPLC. After about 3.5 h, the Sonogashira coupling reaction was complete; additional Cul (0.97 g) was charged. The hydroamination portion of the reaction was continued at 80 °C; reaction progress was monitored by UPLC. After about 20 h, 85.3 % area of the title product was present in solution. The contents of the reactor were cooled to 25 °C and split into two equal portions for separate downstream processing experiments.
A reactor was charged with (.S)-3-amino-l-methyl-3-(prop-2-yn-l-yl)pyrrolidin-2-one hydrochloride salt (1 :1; 7.47 g), 2-chloro-4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine (10.0 g), potassium carbonate (12.67 g) and acetonitrile (23.7 g). With good stirring at ambient temperature, the mixture was sparged with nitrogen for about 10 min. After charging PdCh(dppf) - CH2C12 (150 mg) and Cui (70 mg) and nitrogen sparging for an additional 10 min, the contents of the reactor were heated to about 78 °C; the progress of the reaction was monitored by UPLC. After about 8 h, the contents of the reactor were cooled to 20 °C and isopropyl acetate (52.2 g) was charged. The organic layer was treated with water (60 g) for about 10 min, and the layers were separated. The organic solution was treated twice for about 15 min (50 mL per treatment) with an aqueous solution prepared from NaCl (60 g), concentrated NH*0H solution (20 mL), L-cysteine (2 g) and water (200 mL). Following the layer separation, the organic phase was washed with brine (50 mL), concentrated to about 30 mL in vacuo and re-concentrated twice from isopropyl acetate (43.5 g per concentration) to a volume of about 30 mL each time. Solids were removed by filtration and washed with isopropyl acetate (8.7 g). By internal standard 1H NMR analysis.
the solution contained 13.85 g (97%) of (S)-3 -amino- l-methyl-3 -(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pynolidin-2-one. Following additions of Cui (70 mg) and isopropyl acetate (16.5 g) and sparging the solution with nitrogen for about 10 min with good stirring, the contents of the reactor were heated to about 75 °C; the progress of the reaction was monitored by UPLC. After about 24 h, the contents of the reactor were cooled to about 40 °C over about 3 h and aged for about 20 h. Solids were isolated by filtration, washed twice with isopropyl acetate (24.4 g per wash) and dried to constant weight in vacuo at 40 °C to give 11.0 g (77%) of the title product; purity >99.9 % area.
Example 4: Preparation of (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1)
A reactor was charged with one-half of the product solution (27.63 g) from Example 3 Procedure B (containing 7.12 g of the product (theory)) and acetonitrile (22.1 g). After briefly sparging the solution with nitrogen, a solution of tert-butylamine - borane (1.31 g) in acetonitrile (14.2 g) was charged slowly over about 5 min; the progress of the reaction, performed at 25 °C, was monitored by UPLC. After about 5 h, the contents of the reactor were cooled to 0 - 5 °C and 5M aqueous HC1 solution (28 mL) was slowly charged under a nitrogen sweep. Following the addition, the contents of the reactor were warmed to 25 °C and aged for about 15 min. The contents of the reactor were transferred to a 500 mL Erlenmeyer flask. The reactor was rinsed forward into the flask with acetonitrile (8.4 g). A 50 wt% aqueous K3PO4 solution (71 mL) was slowly added with good stirring over about 30 min and the mixture was aged for about 30 min. The layers were separated and the aqueous layer was back-extracted with acetonitrile (11.1 g). The combined organic layers were washed with brine (28 mL) and concentrated in vacuo to a volume of about 18 mL (KF = 19.7%). Acetonitrile (25.3 g) was added and the mixture was re-concentrated to about 18 mL. After three repetitions of this re-concentration process (KF <1%), solids were removed by
filtration and the filter cake was washed with acetonitrile (5.6 g). The KF of the filtrate (21 .93 g) was adjusted to 2.7% by charging water (0.57 g). The solution was warmed to about 50 °C, a 7.5M aqueous solution of H2SO4 (2.44 mL) was added dropwise over about 10 min and the resulting slurry was aged at about 50 °C for about 1 h. The slurry was cooled to about 25 °C over 45 min, isopropanol (5.5 g) was charged and the slurry was aged over the weekend. The slurry was cooled to 0-5 °C and aged for about 1 h. Solids were isolated by filtration, washed with cold (0 - 5 °C) acetonitrile - MTBE (1:1 v/v, 14 mL) and cold (0 - 5 °C) MTBE (10.4 g), and dried to constant weight in vacuo at 40 °C to yield 3.44 g (39% from 2-chloro-4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine) of the title product; 98.5 % area purity.
Procedure B
A reactor was charged with one-half of the product solution (27.17 g) from Example 3 Procedure B (containing 7.12 g of the product (theory)). The acetonitrile solution was stirred three times for about 15 min with an aqueous NH4OH - brine solution (35 mL per treatment; the solution was prepared by adding concentrated NH4OH solution (10 mL) into brine (100 mL)). The organic solution was stirred twice for about 30 min with an aqueous NH4OH - brine - L-cysteine solution (35 mL per treatment; the solution was prepared by adding concentrated NH4OH solution ( 10 mL) and L-cysteine (1.22 g) into brine (100 mL)).
Following the last aqueous treatment, solids precipitated from the acetonitrile solution. The solids were isolated by filtration, washed with water (7 g; 14 g) and partially dried under suction for about 10 min. The solid was dissolved in acetonitrile (39.5 g) and the solution was concentrated in vacuo to a volume of about 18 mL (KF = 7.9%). Acetonitrile (25.3 g) was added and the mixture was re-concentrated to about 18 mL. After two repetitions of this re-concentration process (KF <0.1%), the solution was briefly sparged with nitrogen and a solution of tert-butylamine - borane (1.35 g) in acetonitrile (14.2 g) was charged slowly over about 15 min; the charging apparatus was rinsed forward into the reactor with acetonitrile (4 g). The progress of the reaction, performed at 25 °C, was monitored by UPLC. After about 2 h, the contents of the reactor were cooled to 0 - 5 °C and 5M aqueous HC1 solution (28 mL) was slowly charged over about 15 min under a nitrogen sweep. Following the addition, the contents of the reactor were warmed to 10 °C and aged for about 20 min. The contents of the reactor were cooled to 0 - 5 °C and a 50 wt% aqueous K3PO4 solution (71 mL) was slowly- added with good stirring over about 15 min. The contents of the reactor were warmed to about 10 °C and aged for about 15 min. The layers were separated and the aqueous layer was
back-extracted with acetonitrile (11.1 g). The combined organic layers were washed with brine (28 mL) and concentrated in vacuo to a volume of about 18 mL. Acetonitrile (25.3 g) was added (KF = 7.4%) and the mixture was re-concentrated to about 18 mL. After three repetitions of this re-concentration process (KF <1%; final concentration was to a volume of about 21 mL), solids were removed by filtration and the filter cake was washed with acetonitrile (5.6 g). The KF of the filtrate (21.93 g) was adjusted to 2.6% by charging water (0.67 g). The solution was warmed to about 50 °C, a 7.5M aqueous solution of H2SO4 (2.44 mL) was added dropwise over about 10 min and the resulting slurry was aged at about 50 °C for about 1 h. The slurry was cooled to about 25 °C over 45 min, isopropanol (5.5 g) was charged and the slurry was aged overnight. The slurry was cooled to 0 - 5 °C and aged for about 1 h. Solids were isolated by filtration, washed with cold (0 - 5 °C) acetonitrile - MTBE (1 : 1 v/v, 14 mL) and cold (0 - 5 °C) MTBE (10.4 g) and dried to constant weight in vacuo at 40 °C to yield 3.69 g (41% from 2-chloro-4-methyl-6-[4- (trifluoromethyl)phenyl]pyrimidine) of the title product; 98 % area purity.
A reactor was charged with (S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]non-l-en-6-one (1175 g) and acetonitrile (6.42 kg). With good stirring, a solution of tert-butylamine - borane (215.7 g) in acetonitrile (2.30 kg) was charged over 35 - 40 min; the charging vessel and line was rinsed forward into the reactor with acetonitrile (0.93 kg). The progress of the reaction, performed at 20 °C, was monitored by UPLC. After about 2.75 h, the contents of the reactor were cooled to 10 - 15 °C and 5M aqueous HC1 solution (4.7 L) was charged over 30 - 35 min under a nitrogen sweep while maintaining a reaction temperature of ≤ 20 °C. Following the addition, the contents of the reactor were aged for about 45 min. A 50 wt% aqueous K3PO4 solution (18.90 kg) was slowly added with good stirring over about 70 min while maintaining a reaction temperature of ≤ 20 °C, and the mixture was aged for about 20 min. The layers were separated and the aqueous layer was back-extracted with acetonitrile (1.84 kg). The combined organic layers were washed with brine (5.63 kg) and the organic layer
was concentrated in vacuo to a volume of 2.9 - 3.0 L. Acetonitrile (4.16 kg) was added and the mixture (KF = 3.1%) was re-concentrated to about 3.0 L. Acetonitrile (4.15 kg) was charged, solids were removed by filtration and the filter cake was washed with acetonitrile (0.92 kg). The KF of the filtrate (7424 g) was adjusted from 0.54% to 2.45% by charging water (150.5 g). The solution was warmed to about 50 °C, a 7.5M aqueous solution of H2SO4 (0.57 kg) was added dropwise over about 1 h and the resulting slurry was aged at about 50 °C for about 1 h . The slurry was cooled to about 20 °C over 45 min, isopropanol (0.93 kg) was charged and the slurry was aged for about 12 h. The slurry was cooled to 0- 5 °C over about 45 min and aged for about 2.25 h. Solids were isolated by filtration, washed with cold (0 - 5 °C) acetonitrile - MTBE (1:1 v/v, 1.84 kg) and cold (0 - 5 °C) MTBE (1.73 kg) and dried to constant weight in vacuo at 40 °C to yield 1065 g (72% ) of the title product; 98.9 % area.
Example 5: Recrystallization of (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1)
A reactor was charged with (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1) (524 g), distilled water (0.91 kg) and acetone (1.70 kg) and the mixture was heated to solution at 35 - 37 °C with good stirring. The solution was polish filtered into a second reactor and was reheated to solution at 38 - 40 °C. Over about 3.5 h, acetone (6.38 L) was charged while maintaining a reaction temperature of 38 - 40 °C. The slurry was aged for about 1 h, cooled to about 25 °C over about 1 h, aged for about 18 h, cooled to 0 - 5 °C over about 1 h and aged for about 3 h. Solids were isolated by filtration, twice washed with cold (0 - 5 °C) acetone (0.33 kg per wash) and dried to constant weight in vacuo at 50 °C to give 433 g (83%) of the title compound; 99.9 % area.
Under an inert atmosphere of nitrogen, a reactor was charged with NMP (49.6 kg), diethyl carbonate (59.1 kg) and THF (423 kg), and the solution was cooled to 0 - 5 °C with good stirring. A freshly titrated solution of LDA in PhEt (13.07 wt%; 2.0 eq) was added slowly followed by warming the contents of the reactor to 25 °C; the progress of the reaction was monitored by GC. After aging for about 2 h, the slurry was cooled to 0 - 5 °C and a solution of propargyl bromide in toluene (80 wt%» 1.0 equiv, assay corrected (NMR internal standard)) was added slowly followed by warming the contents of the reactor to 25 °C; the progress of the reaction was monitored by HPLC. After about 6 h, an additional charge of propargyl bromide in toluene (80 wt%, 0.03 equiv) was added and the reaction was continued at 25 °C. After an additional 2 h, water (198 kg) was added and the solution was stirred at 25 °C; the progress of the reaction was monitored by HPLC. After about 1.5 h, concentrated HC1 solution was added to about pH 0.6, NaCI (25.3 kg) was charged and the contents of the reactor were warmed to 45 °C. After four extractions with isopropyl acetate (129.5 kg per extraction), the combined organic layers were concentrated in vacuo to about 350 L, and the resulting solution was cooled to 25 °C. After slowly charging heptane (202 kg), the contents of the reactor were cooled to 0 - 5 °C and aged for about 1 h. Solids were isolated by filtration, washed with isopropyl acetate - heptane (1:6 v/v, 35.3 kg) and dried to constant weight in vacuo at 45 °C to yield 69.9 kg (68%, assay corrected) of the title compound. A second crop of 4.9 kg (5%, assay corrected) of the title compound was also obtained for a combined yield of 74.8 kg (73%, assay corrected).
Example 7: Preparation of (S)-2-hydroxy-l-phenylethan-l-aminium (S)-l-methyl-2-oxo- 3-(prop-2-yn-l-yl)pyrrolidine-3-carboxylate (1:1)
o
A reactor was charged with l-methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (75.2 kg activity) and isopropanol (413.3 kg) and the mixture was heated to 50 °C with good stirring. A solution of (S)-2-phenylglycinol (57.0 kg) in water (41.9 kg), also heated to 50
°C, was added to the isopropanol solution of the racemic acid, and the reactor and charging line which contained the aqueous solution were rinsed forward with isopropanol (26.0 kg). The resulting solution was aged for about 20 min at 50 °C, slowly cooled to about 41 °C and was seeded (100 g). After aging for about 30 min, the slurry was cooled to 0 - 5 °C and aged for about 4 h. Solids were isolated by filtration, washed twice with isopropanol - MTBE (5/95 v/v, 279.3 kg per wash) and dried to constant weight in vacuo at 30 °C to give 57.3 kg (41%) of the title compound; chiral purity: 99.4%.
A reactor was charged with (.S)-2-hydroxy-l-phenylethan-l-aminium (S)-l-methyl-2-oxo-3- (prop-2-yn-l-yl)pyrrolidine-3 -carboxylate (1:1, 47.2 kg activity) and water (141 kg), and the contents of the reactor were cooled to 0 - 5 °C with good stirring. Concentrated HC1 solution (16.48 kg) was added slowly to about pH 1.43, the contents of the reactor were warmed to 20 °C and aged for about 2 h. After charging NaCl (23.6 kg), the solution was heated to about 45 °C and was extracted three times with 2-methylTHF (201.5 kg per extraction). The combined organic extracts were washed with acidic brine (164.3 kg; acidified with concentrated HC1 solution (60 g)), dried over anhydrous MgSO* (4.7 kg) for about 1 h, filtered and the spent filter cake was washed with 2-methylTHF (40.3 kg). The combined filtrate and wash were concentrated in vacuo to about 120 L, cooled to 20 - 25 °C and heptane (290.5 kg) was slowly added. The contents of the reactor were cooled to 0 - 5 °C and aged for about 1 h. Solids were isolated by filtration, washed with 2-methylTHF - heptane (1/9 v/v, 66.1 kg) and dried to constant weight in vacuo at 45 °C to give 24.36 kg (91%) of the title compound; chiral purity: 100%.
Example 9: Preparation of tert-butyl (S)-(l-methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidin- 3- yl) carb am ate
Procedure A: batch process
Under an inert atmosphere of nitrogen a reactor was charged with (S)-l-methyl-2-oxo-3- (prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (750 g), N-methylmorpholine (435 g) and toluene (9.14 kg). With good stirring, the contents of the reactor were heated to 77 - 80 °C followed by slow addition of DPPA (1173 g) over about 15 min; the charging vessel and line were rinsed forward into the reactor with toluene (653 g). The progress of the reaction was monitored by GC. After about 5 h, DMAP (222.5 g) and t-BuOH (1687 g) were charged, and the reaction was continued at 77 - 80 °C; the progress of the reaction was monitored by GC. After about 15 h, the contents of the reactor were cooled to 20 - 25 °C, basic alumina (2.25 kg) was charged and stirring was continued for about 30 min. Solids were removed by filtration through a pad of basic alumina (3.75 kg); the spent filter cake was washed twice with toluene (2.0 kg per wash). The filtrate was concentrated in vacuo to a volume of about 1.5 L and was diluted with dichloromethane (10.0 kg). The organic phase was treated twice for about 15 min with 2M aqueous NH4OH solution (4.5 L per treatment), treated twice for about 15 min with IM aqueous HC1 solution (7.5 L per treatment) and dried over anhydrous MgSO* (750 g) for about 1 h. Solids were removed by filtration and washed twice with dichloromethane (2 kg per wash). The filtrate was concentrated in vacuo to a volume of about 1.5 L and MTBE - heptane (1:2 v/v, 3.75 L) was added over about 20 min at 20 - 25 °C with good stirring. The slurry was cooled to 0 - 5 °C and was aged for about 2 h. Solids were isolated by filtration, washed twice with heptane (1.0 kg per wash) and dried to constant weight in vacuo at 30 °C to give 690 g (66%) of the title compound; 98.0 % area purity.
Feed 1 Solution: (S)-l-methyl-2-oxo-3-(prop-2-yn-l-yl)pyrrolidine-3-carboxylic acid (24.34 kg),
/V-methylmorpholine (27.1 kg) and r-BuOH (99.6 kg); this feed solution was maintained at 25- 35 °C during the run
Feed 2 Solution: DPPA (46.02 kg) and toluene (218.1 kg); this feed solution was maintained at 5 - 25 °C during the run
Pipe In Series Reactor:
• two units connected in series
• each unit contains 6 pipes, each of about 1 m in length o up flow: three 1 inch diameter pipes o down flow: three 1/4 inch diameter pipes
Flow Rates:
• Feed 1: 44.6 g / min
• Feed 2: 75.3 g / min
Residence Time: 1 h
Reaction Temperature: 80 °C
After reaching steady state, eluent from the flow reactor was collected for about 42 h into a continuously stirred tank reactor which was pre-heated to about 80 °C. Following the collection period, the contents of the reactor were aged at about 80 °C; the progress of the reaction was monitored by HPLC. After about 18 h, the reaction mixture was cooled and with good stirring, was quenched with a solution composed of NaNCh (9.0 kg), 25% aqueous NaOH (16.28 kg) and water (54.0 kg). After stirring for about 12 h at 20 - 30 °C, the layers were separated and the aqueous layer was back extracted with toluene (285 kg). The combined organic layers were washed four times with 4.5% aqueous NaHCO3 solution (54.4 kg per wash) and with water (22 kg). The organic layer was concentrated in vacuo to about 33 L, additional toluene (18.9 kg) was added and the contents of the reactor were heated to about 50 °C, cooled to 20 °C, further cooled to -10 °C and aged for about 2.5 h. Solids were isolated by filtration, washed with heptane (29.9 kg) and dried to constant weight in vacuo at 50 °C to yield 17.48 kg (57% based on processed starting material) of the title product; 100 % area; chiral purity: 100%.
Example 10: Preparation of (S)-3-amino-l-methyl-3-(3-(4-methyI-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1)
Part A: a reactor was charged with 2-chloro-4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidine (20.0 kg) and tert-butyl (S)-(l-methyl-2-oxo-3-(prop-2- yn-l-yl)pyrrolidin-3-yl)carbamate (20.1 kg). After three vacuum / nitrogen break cycles, the reactor was charged with isopropyl acetate (44 kg) and the contents of the reactor were stirred at 20 °C. After charging diisopropylamine (8.2 kg) the container and transfer line were rinsed forward into the reactor with isopropyl acetate (4.4 kg). After four vacuum / nitrogen break cycles the reactor was charged with a slurry composed of dichloro[bis[2- (diphenylphosphino)phenyl|ether]palladium (II) (131 g) in isopropyl acetate (1.3 kg) followed by a slurry of Cui (71 g) in isopropyl acetate (1.3 kg). Following each charge, the container and transfer line were rinsed forward into the reactor with isopropyl acetate (0.9 kg per container). The contents of the reactor were warmed to 75 - 80 °C (target: 78 °C); the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to 18 - 23 °C, aged for about 20 min and filtered. The spent filter cake was washed with isopropyl acetate (34.9 kg); the combined filtrate and wash were stirred for about 15 min to give an isopropyl acetate solution of tert-butyl (S)-(l-methyl-3-(3-(4-methyl- 6-(4-(trifhioromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)-2-oxopyrrolidin-3- yl) carbamate.
Part B: To the solution prepared in Part A at 20 °C was charged acetonitrile (56.9 kg). With good stirring, methansulfonic acid (21.1 kg) was added over about 15 min while controlling
the reaction temperature at < 26 °C. Following the addition, the container and transfer line were rinsed forward into the reactor with acetonitrile (7.9 kg) and the contents of the reactor were heated to 60 - 70 °C (target: 65 °C); the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to about 45 °C and purified water (179.3 kg) was charged over about 90 min while maintaining a reaction temperature of 45 - 50 °C. Following the addition, the contents of the reactor were cooled to 18 - 25 °C and aged for about 15 min. The layers were separated and the lower aqueous layer was basified (pH >12) with 50 wt% aqueous K3PO4 solution (33.60 kg) over about 30 min while maintaining a reaction temperature of 20 - 25 °C. Isopropyl acetate (62.6 kg) was charged and the contents of the reactor were stirred for about 10 min. The layers were separated and the lower aqueous layer was back extracted with isopropyl acetate (41.1 kg). The combined organic layers were concentrated in vacuo to a volume of about 108 L. Isopropyl acetate (156.3 kg) was charged and the solution was concentrated in vacuo to a volume of about 72 L. Isopropyl acetate (156.3 kg) was charged and the solution was concentrated in vacuo to a volume of about 72 L (KF = 0.6 % (limit: <1.6%)) to give an isopropyl acetate solution of (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2- yn- l-yl)pyrrolidin-2-one.
Part C: The solution prepared in Part B was polish filtered. The reactor which contained the solution and the transfer line were rinsed forward with isopropyl acetate (10 kg). The contents of the reactor were warmed to 30 - 40 °C (target: 35 °C) with good stirring. A solution of salicylic acid ( 12.2 kg) in isopropyl acetate (63.5 kg) was added over about 110 min while maintaining a reaction temperature of 32 - 36 °C. Following the addition the contents of the reactor were aged at 30 - 40 °C (target: 35 °C) for about 3 h, cooled to 24 - 26 °C (target: 25 °C) over about 2 h, cooled to -5 to -15 °C (target: -10 °C) over about 80 min and aged for about 35 min. Solids were isolated by filtration, twice washed with cold (0 - 5 °C) MTBE - ACN (1:1 v/v, 59 L per wash), dried on the filter (jacket temperature: 60 °C) under suction while applying a stream of warm nitrogen (60 °C) for about 14 h followed by further drying on the filter under suction for about 33 h to give 28.9 kg (75%) of the title compound; purify: 97.6 % area; chiral purify: 99.8 % area.
Example 11: Preparation of (S)-7-metiiyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]non-1-en-6-one
Description 1
A reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (333 mg) and dichloromethane (2 mL). With good stirring, 20 wt% aqueous K3PO4 solution was charged. Following salt dissolution and a pH measurement of the aqueous layer (>12), the layers were separated and the upper aqueous layer was back extracted with dichloromethane. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to a viscous, immobile syrup which was dissolved in isopropanol (2 mL). Following addition of AgNTf2 (17 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 24 h. UPLC analysis showed that 94 % area of the title compound was present in the solution.
A reactor was charged with a solution of (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrinudin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one (1.57 g) in
acetonitrile (6.4 mL). Following addition of AgNTf2 (110 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 25 h. UPLC analysis showed that 89 % area of the title compound was present in the solution.
Part A: A reactor was charged with 1,10-phenanthroline (465 mg) and MeOH (15 mL). With good stirring at ambient temperature, a solution of AgNTf2 (1.00 g) in water (15 mL) was added. After aging for about 15 min, solids were isolated by filtration, washed with MeOH and dried to constant weight in vacuo at ambient temperature to give 920 mg (78%) of Ag(phen)1.4NTf2. 1H and 19F NMR spectra (d6-DMSO) using 1,4-difluorobenzene as an internal standard indicated a mol ratio of AgNTf2 : 1,10- phenanthroline = 1:1.4.
Part B: A reactor was charged with a solution of (5)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pynolidin-2-one (1 .10 g) in isopropanol (4.5 mL). Following addition of Ag(phen)i.4NTf2 (161 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 20 h. UPLC analysis showed that 96 % area of the title compound was present in the solution.
Description 4
Part A: A reactor was charged with 1,10-phenanthroline (2.00 g) and MeOH (70 mL). With good stirring at ambient temperature, a solution of AgOTf (2.85 g) in water (70 mL) was added. After aging for about 15 min, solids were isolated by filtration, washed with MeOH and dried to constant weight in vacuo at ambient temperature to give 3.35 g (>100%) of Ag(phen)2.5OTf. 1H and 19F NMR spectra (d6-DMSO) using 1 ,4-difluorobenzene as an internal standard indicated a mol ratio of AgOTf : 1,10- phenanthroline = 1 :2.5.
Part B: a reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidm-2-one, salicylic acid salt (1:1) (6 g) and dichloromethane (60 mL). With good stirring, 20 wt% aqueous K3PO4 solution was charged. Following salt dissolution and a pH measurement of the aqueous layer (≥12), the layers were separated and the upper aqueous layer was back extracted with dichloromethane. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to a viscous, immobile syrup which was dissolved in isopropanol (18 mL). Following addition of Ag(phen)2.5OTf (497 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 20 h. UPLC analysis showed that 95 % area of the title compound was present in the solution.
Description 5
A reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (333 mg) and dichloromethane (2 mL). With good stirring, 20 wt% aqueous K3PO4 solution was charged. Following salt dissolution and a pH measurement of the aqueous layer (>12), the layers were separated and the upper aqueous layer was back extracted with dichloromethane. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to a viscous, immobile syrup which was dissolved in isopropanol (1 mL). Following addition of dichloro[bis[2-(diphenylphosphino)phenyl]ether]palladium (II) (36 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 40 h. UPLC analysis showed that 56 % area of the title compound was present in the solution.
A reactor was charged with a solution of (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one (1.0 g) in isopropyl acetate (5.0 mL). Following addition of Cui (20 mg) and three vacuum / nitrogen break
cycles, the resulting solution was heated to about 80 °C and aged for about 7 h. UPLC analysis showed that 90 % area of the title compound was present in the solution.
A reactor was charged with a solution of (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidm-2-one (1.0 g) in acetonitrile (5.0 mL). Following addition of Cul (20 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 7 h. UPLC analysis showed that 68 % area of the title compound was present in the solution.
A reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (7 g) and dichloromethane (70 mL). With good stirring, 20 wt% aqueous K3PO4 solution (39.3 g) was charged. Following salt dissolution and a pH measurement of the aqueous layer (≥12), the layers were separated and the upper aqueous layer was back
extracted with dichloromethane. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to a viscous, immobile syrup which was dissolved in isopropyl acetate (42 mL). Following addition of Cui (127 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 3.5 h. UPLC analysis showed that 92 % area of the title compound was present in the solution.
A reactor was charged with (5)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (1.35 g) and acetonitrile (5 mL). Following addition of Cui (20 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 23 h. UPLC analysis showed that 42 % area of the title compound was present in the solution.
A reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (13.5 g) and isopropanol (40 mL). Following addition of Cui (489 mg) and three vacuum / nitrogen break cycles, the resulting solution was heated to about 80 °C and aged for about 11 h. UPLC analysis showed that 89 % area of the title compound was present in the solution.
Description 11
Part A: a reactor was charged with 2-chloro-4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidine (10.0 g) and tert-butyl (S)-(l-methyl-2-oxo-3-(prop-2-yn- l-yl)pyrrolidin-3-yl)carbamate (9.99 g), diisopropylamine (4.08 g), dichloro[bis[2- (diphenylphosphino)phenyl]ether]palladium (II) (66 mg), Cui (35 mg) and isopropyl acetate (26.1 g). The contents of tire reactor were sparged with nitrogen for about 15 min then warmed to 80 °C; the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to 20 °C and filtered. The spent filter cake was wrashed twice with isopropyl acetate (8.7 g per wash); the combined filtrate and wash were stirred briefly to give an isopropyl acetate solution of tert-butyl (S)-(l-methyl-3-(3-(4-methyl- 6-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)-2-oxopyrrolidin-3-yl)carbamate (58.4 g). By NMR internal standard analysis, the solution contained 13.6 g (76%) of the desired product.
Part B: To the solution prepared in Part A at 20 °C was charged acetonitrile (22.1 g) and methansulfonic acid (6.96 g) and the contents of the reactor were heated to 65 °C; the progress of the reaction was monitored by UPLC. Upon completion, water (70 mL) was charged and the contents of the reactor were cooled to about 20 °C. The layers were separated and the lower aqueous layer was basified (pH ≥12) with 50 wt% aqueous K3PO4 solution (52 mL). Isopropyl acetate (24.4 g) was charged, the layers were separated and the lower aqueous layer was back extracted with isopropyl acetate (12.2 g). The combined organic layers were concentrated in vacuo to a volume of about 30 mL. Isopropyl acetate (60.9 g) was charged and tire solution was concentrated in vacuo to a volume of about 30
mL; this re-concentration was repeated one time. Solids were removed by filtration and washed with isopropyl acetate (8.7 g) to give an isopropyl acetate solution of (S)-3-amino-l- methyl-3-(3-(4-methyl-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-1- yl)pyrrolidin-2-one (50.7 g). By 1HNMR internal standard analysis, the solution contained 10.9 g (100 %) of the desired product.
Part C: The solution prepared in Part B was sparged with nitrogen for about 15 min. After charging Cui (267 mg), the contents of the reactor were sparged with nitrogen for about 15 min then heated to 75 °C; the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to 40 °C and aged for about 16 h. Solids w-ere isolated by filtration, washed twice with isopropyl acetate (19.1g per wash) and dried to constant weight in vacuo at 40 °C to give 7.4g (68%) of the tide compound; purity-: 99.9 % area.
Part A: a reactor was charged with (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one, salicylic acid salt (1:1) (28.55 kg) and dichloromethane (310.0 kg). With good stirring, the reaction temperature was adjusted to 15 - 25 °C (target: 18 °C) and 20 wt% aqueous K3PO4 solution (210.85 kg) was charged over about 25 min while maintaining a reaction temperature of ≤30 °C. After aging for about 30 min, the layers were separated and the upper aqueous layer was back extracted with dichloromethane (124.2 kg). The combined organic layers were
concentrated in vacuo to a volume of about 70 L, isopropyl acetate (102.15 kg) was charged, the solution was concentrated in vacuo to a volume of about 70 L, isopropyl acetate (101.9 kg) was charged and the solution was concentrated in vacuo to a volume of about 47 L, isopropyl acetate (103.85 kg) was charged and the solution was concentrated in vacuo to a volume of about 47 L (KF ≤1.0%). The solution was polish filtered, and the reactor, polish filter and transfer line were rinsed forward with isopropyl acetate (20.6 kg) to give an isopropyl acetate solution of (S)-3-amino-l-methyl-3-(3-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)prop-2-yn-l-yl)pyrrolidin-2-one.
Part B:
The solution prepared in Part A at 15 - 25 °C (target: 20 °C) was subjected to four vacuum / nitrogen break cycles. After charging a slurry of CuI (434 g) in isopropyl acetate (1.0 kg) to the reactor, the container and charging line were rinsed forward into the reactor with isopropyl acetate (0.6 kg). After four vacuum / nitrogen break cycles and sparging the solution with nitrogen for about 30 min, the contents of the reactor were heated to 70 - 80 °C (target: 75 °C); the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to 37 - 43 °C (target: 40 °C) over about 3.5 h; the progress of the crystallization was monitored by ReactIR. Upon completion, the contents of the reactor were aged at 37 - 40 °C (target: 40 °C) for about 2 h. Solids were isolated by filtration, washed twice with isopropyl acetate (29.8 kg per wash), dried on the filter for about 1 h under a stream of nitrogen, dried on the filter (jacket temperature: 40 °C) while applying a stream of warm nitrogen (40 °C) for about 15 h followed by further drying on the filter under suction for about 15 h to give 13.1 kg (62%) of the title compound; purity: 99.9 % area.
Example 12: Preparation of (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1)
Under an inert atmosphere of nitrogen a reactor was charged with (S)-7-methyl-2-(4-methyl- 6-(4-(trifluoromethy l)phenyl)pyriniidin-2-y 1)- 1 ,7-diazaspiro [4 ,4]non- 1 -en-6-one ( 13.0 kg) and acetonitrile (71.7 kg) and with good stirring the contents of the reactor were adjusted to 15 - 25 °C (target: 19 °C). A solution of tert-butylamine - borane complex (2.4 kg) in acetonitrile (25.7 kg) was charged over 35 - 40 min while maintaining a reaction temperature of ≤20 °C. Following the addition, the vessel and charging line were rinsed forward into the reactor with acetonitrile (10.3 kg); the progress of the reaction was monitored by UPLC. Upon completion, the contents of the reactor were cooled to 10 - 15 °C (target: 12 °C) and 5M aqueous HC1 solution (55.55 kg) was added over about 1 h while maintaining a reaction temperature of ≤20 °C. The contents of the reactor were aged for about 30 min. With continued good stirring, 50 wt% aqueous K3PO4 solution (209.45 kg) was charged over 75 - 80 min while maintaining a reaction temperature of <20 °C. The contents of the reactor were aged for about 20 min. The layers were separated, the lower aqueous layer was back extracted with acetonitrile (20.5 kg) and the combined organic layers were washed with brine (59.7 kg). The combined organic layers were concentrated in vacuo to a volume of about 33 L. After charging acetonitrile (46.3 kg), the contents of the reactor were concentrated in vacuo to a volume of about 33 L. After charging acetonitrile (46.2 kg), the contents of the reactor were concentrated in vacuo to a volume of about 33 L. After charging acetonitrile (46.1 kg) a KF <3% was measured and the contents of the reactor were aged for about 1 h. Following a polish filtration, the reactor, polish filter and transfer line were rinsed forward with acetonitrile (10.2 kg). To the solution (KF 1.2%) was charged water (1.1 kg; final KF 2.3%) and the contents of the reactor were warmed to 48 - 53 °C (target: 50 °C). With good stirring, 7.5M aqueous sulfuric acid solution (6.25 kg) was added over about 1 h, the slurry- was aged for about 1 h then cooled to 18 - 23 °C (target: 20 °C) over about 1 h. Isopropanol (10.2 kg) was charged over about 25 min, the slurry was aged for about 12 h, cooled to 0 - 5 °C over about 2.25 h and aged for about 2 h. Solids were isolated by filtration, washed with cold (0 - 5 °C) MTBE - ACN (1:1 v/v, 20 kg), cold (0 - 5 °C) MTBE (19.3 kg), dried on the filter while applying a stream of nitrogen for about 90 min, dried on the filter (jacket temperature: 40 °C) while applying a stream of warm nitrogen (40 °C) for about 12 h followed by further drying on the filter under suction for about 17 h to give 11.95 kg (73%) of the title compound; purity: 98.6 % area.
Example 13: Recrystallization of (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1)
A reactor was charged with (2R,5S)-7-methyl-2-(4-methyl-6-(4- (trifluoromethyl)phenyl)pyrimidin-2-yl)-l,7-diazaspiro[4.4]nonan-6-one, sulfuric acid salt (1:1) (11 .95 kg), purified water (23.25 kg) and acetone (43.9 kg) and the contents of tire reactor were wanned to 35 - 40 °C (target: 39 °C) with good stirring. Following a wash of a polish filter system with a warm aqueous acetone solution (23.45 kg purified water and 43.5 kg acetone; the wash was discarded), the contents of the reactor were polish filtered into a reactor that was pre-heated to 35 - 40 °C (target: 39 °C). To the resulting solution was charged MTBE (210.5 kg) over about 3 h while maintaining a reaction temperature of 35 - 40 °C (target: 39 °C). After aging for about 30 min, the contents of the reactor were cooled to 0 - 5 °C over about 3.5 h and aged for about 30 min. The contents of the reactor were warmed to 38 - 43 °C (target: 40 °C) over about 1.5 h, aged for about 2 h, cooled to 8 - 14 °C (target: 10 °C) over about 4.5 h and aged for about 12 h. Solids were isolated by filtration, washed twice with cold (0 - 5 °C) MTBE - acetone (1 : 1 v/v, 21.5 kg per wash), dried on the filter while applying a stream of nitrogen for about 1 h, dried on the filter (jacket temperature: 60 °C) while applying a stream of warm nitrogen (60 °C) for about 12 h followed by further drying on the filter under suction for about 33.5 h to give 10.14 kg (85%) of the title compound; purity: 99.9 % area.
INCORPORATION BY REFERENCE
All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
EQUIVALENTS
While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
Claims
1. A process for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with a compound of formula (III), in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
2. The process of claim 1, wherein the metal compound is a palladium compound.
3. The process of claim 2, wherein the palladium compound is palladium(II) acetate.
4. The process of any one of claims 1-3, wherein the phosphine is tert- butyldiphenylphosphine.
5. The process of claim 4, wherein the base is diisopropylethylamine.
6. The process of any one of the preceding claims, further comprising reacting the compound of formula (IV) with a compound of formula (V) or a salt thereof in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (VI):
8. A process for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (IV) with a compound of formula (V) or a salt thereof in the presence of a palladium compound, a metal salt and a base, thereby producing a compound of formula (VI):
wherein the metal salt is not a silver salt.
9. The process of claim 8, wherein the compound of formula (V) is a trifluoroacetate salt
10. The process of claim 8, wherein the compound of formula (V) is a hydrochloride salt.
11. The process of claim 8, wherein the compound of formula (V) is not a salt.
12. The process of any one of claims 8-11, wherein the palladium compound is PdCh(dppf)-CH2Ch or PdCh(DPEphos).
13. The process of any one of claims 8-12, wherein the metal salt is copperfl) salt (e.g., copperfl) iodide).
14. The process of any one of claims 8-13, wherein the base is an inorganic base, e.g. potassium carbonate.
15. The process of any one of claims 8-13, wherein the base is an organic base, e.g. diisopropylamine .
16. The process of any one of claims 8-15, wherein the compound of formula (IV) is reacted with the compound of formula (V) in the presence of a solvent.
17. The process of claim 16, wherein the solvent comprises isopropyl acetate or acetonitrile.
18. The process of any one of claims 8-17, wherein the chemical yield of the compound of formula (VI) is at least about 75%.
19. A process for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof comprising:
reacting a compound of formula (II) with a compound of formula (III) in the presence of a metal compound, a phosphine that comprises an alkyl group, and a base, thereby producing a compound of formula (IV):
reacting the compound of formula (IV) with a compound of formula (V) or a salt thereof in the presence of a palladium compound, a copper salt, and a base, thereby producing a compound of formula (VI): and
reducing tire compound of formula (VI), thereby producing the compound of formula (I), or a pharmaceutically acceptable salt thereof:
21. The compound of claim 20, wherein the compound of formula (V) is a trifluoroacetate salt.
22. The compound of claim 20, wherein the compound of formula (V) is a hydrochloride salt.
23. The compound of claim 20, wherein the compound of formula (V) is not a salt.
24. A process for preparing a compound of formula (I)
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (VII) with an azide compound and an amine in the presence of /-butanol, thereby producing a compound of formula (VIII):
(VII) (VIII)
25. The process of claim 24, wherein the azide compound is diphenylphosphoryl azide.
26. The process of claim 24 or 25, wherein the amine is N-methylmorpholine.
27. The process of any one of claims 24-26, wherein the reaction is performed in a batch process.
28. The process of any one of claims 24-26, wherein the reaction is performed in a continuous flow process.
29. The process of any one of claims 24-28, wherein the reaction is performed in the presence of a solvent.
30. The process of claim 29, wherein the solvent comprises toluene.
32. The process of claim 31 , wherein the palladium catalyst is PdCh(DPEphos).
33. The process of claims 31 or 32, wherein tire copper salt is copper(I) iodide.
34. The process any one of claims 31-33, wherein the base is diisopropylamine.
35. The process of any one of claims 31-34, wherein the compound of formula (IV) is reacted with the compound of formula (VIII) in the presence of a solvent.
36. The process of claim 35, wherein the solvent comprises isopropyl acetate.
38. The process of claim 37, wherein tire compound of formula (IXa) is reacted with the acid in the presence of a solvent.
39. The process of claim 38, wherein the solvent comprises acetonitrile.
40. The process of any one of claims 37-39, wherein the acid is methanesulfonic acid.
41. The process of any one of claims 24-30, further comprising i) reacting a compound of formula (IV) with the compound of formula (VIII) in the presence of a palladium compound, a copper salt and a base, thereby producing a compound of formula (IXa) or a salt thereof; and ii) reacting a compound of formula (IXa) with an acid, thereby producing a compound of formula (IX) or a salt thereof
wherein the compound of formula (IXa) is not isolated.
42. The process of claim 41, wherein the palladium catalyst is PdCb(DPEphos).
43. The process of claims 41 or 42, wherein the copper salt is copper(I) iodide.
44. The process any one of claims 41-43, wherein the base is diisopropylamine.
45. The process of any one of claims 41-44, wherein the compound of formula (IV) is reacted with the compound of formula (VIII) in the presence of a solvent.
46. The process of claim 45, wherein the solvent comprises isopropyl acetate.
47. The process of any one of claims 41-46, wherein the compound of formula (IXa) is reacted with the acid in the presence of a solvent.
48. The process of claim 47, wherein the solvent comprises isopropyl acetate and acetonitrile.
49. The process of any one of claims 24-48, further comprising performing a cyclization reaction of the compound of formula (IX), or a salt thereof in the presence of a metal salt to produce a compound of formula (VI):
51. The process of claim 50, wherein the compound of formula (VI) is reduced to the compound of formula (I), or a pharmaceutically acceptable salt thereof in the presence of a boron compound.
52. The process of claim 51, wherein the boron compound is a borane.
53. The process of claim 52, wherein the borane is borane-tert-butyl amine complex.
55. The process of claim 54, wherein the compound of formula (I) is a hydrogen sulfate salt.
56. The process of claim 54 or 55, wherein the solvent comprises water and acetone.
57. The process of any one of claims 54-56, wherein the solvent further comprises methyl r-butyl ether.
58. The process of any one of claims 54-57, wherein the chemical yield of the process is at least about 80%.
59. The process of any one of claims 54-58, wherein the process provides the compound of formula (I) with a purity of at least about 99%.
61. The process of claim 60, wherein the azide compound is diphenylphosphoryl azide.
62. The process of claim 60 or 61, wherein the amine is N-methylmorpholine.
63. The process of any one of claims 60-62, wherein the reaction is performed in a batch process.
64. The process of any one of claims 60-63, wherein the reaction is performed in the presence of a solvent.
65. The process of claim 64, wherein the solvent comprises toluene.
66. The process of any one of claims 60-65, wherein the base is aqueous sodium hydroxide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126873P | 2020-12-17 | 2020-12-17 | |
US63/126,873 | 2020-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022133097A1 true WO2022133097A1 (en) | 2022-06-23 |
Family
ID=82058702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/063825 WO2022133097A1 (en) | 2020-12-17 | 2021-12-16 | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022133097A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013175205A1 (en) * | 2012-05-22 | 2013-11-28 | Convergence Pharmaceuticals Limited | Novel Compounds |
WO2017075056A1 (en) * | 2015-10-26 | 2017-05-04 | Gilead Apollo, Llc | Acc inhibitors and uses thereof |
-
2021
- 2021-12-16 WO PCT/US2021/063825 patent/WO2022133097A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013175205A1 (en) * | 2012-05-22 | 2013-11-28 | Convergence Pharmaceuticals Limited | Novel Compounds |
WO2013175206A1 (en) * | 2012-05-22 | 2013-11-28 | Convergence Pharmaceuticals Limited | Novel compounds |
WO2017075056A1 (en) * | 2015-10-26 | 2017-05-04 | Gilead Apollo, Llc | Acc inhibitors and uses thereof |
Non-Patent Citations (1)
Title |
---|
MARTIN RUBEN, BUCHWALD STEPHEN L.: "Palladium-Catalyzed Suzuki−Miyaura Cross-Coupling Reactions Employing Dialkylbiaryl Phosphine Ligands", ACCOUNTS OF CHEMICAL RESEARCH, ACS , WASHINGTON , DC, US, vol. 41, no. 11, 18 November 2008 (2008-11-18), US , pages 1461 - 1473, XP055943277, ISSN: 0001-4842, DOI: 10.1021/ar800036s * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102985416B (en) | Process of preparing a thrombin specific inhibitor | |
EP2121605B1 (en) | Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | |
EP3313841A1 (en) | Process for the preparation of a xanthine-based compound | |
JP7025411B2 (en) | Method for producing indole carboxamide compound | |
AU2005269634A1 (en) | Synthesis of 6,7-dihydro-5H-imidazo(1,2-a)imidazole-3-sulfonic acid amides | |
CA2813571A1 (en) | Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3 | |
WO2022133097A1 (en) | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels | |
WO2020210485A1 (en) | Process for preparing alpha-carboxamide pyrrolidine derivatives | |
US6703512B1 (en) | Intermediates for the production of quinolone carboxylic acid derivatives | |
EP1215206B1 (en) | Processes for the preparation of 4(5)-amino-5(4)-carboxamidoimidazoles and intermediates thereof | |
CN116265466A (en) | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels | |
US20220162164A1 (en) | Processes for preparing alpha-carboxamide pyrrolidine derivatives | |
AU2010276490B2 (en) | Enantio- and stereo-specific syntheses of beta-amino-alpha- hydroxy amides | |
NZ502077A (en) | Crystalline roxifiban | |
IT201800006337A1 (en) | LIFITEGRAST PREPARATION PROCEDURE | |
US6407258B1 (en) | Method for producing S-alkyl(aryl)-substituted imidazol derivatives | |
JP4699582B2 (en) | Method for producing 1H-4 (5) -aminoimidazole-5 (4) -carboxamide | |
Rodríguez et al. | Liquid phase organic synthesis of 3, 5-disubstituted 1, 3, 5-thia-diazinane-2-thione derivatives on polyethylene glycol (PEG) support | |
PL191196B1 (en) | Method of obtaining nmda antagonists | |
CN116655557A (en) | Benzothiazole compound, preparation method and application thereof | |
SU1133272A1 (en) | Di-n-oxysuccinimide ester of oxalic acid as reagent for synthesis of n-oxysuccinimide esters of n-substituted amino acids | |
AU4357700A (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
JPH06199781A (en) | Production of optically active 4-mercapto-2-pyrrolidone derivative and its synthetic intermediate | |
ITMI20120391A1 (en) | PROCEDURE FOR THE SYNTHESIS OF A USEFUL CYCLOPROPYLAMID INTERMEDIATE IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR | |
MXPA99005398A (en) | Process for the preparation of nmda antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21907824 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21907824 Country of ref document: EP Kind code of ref document: A1 |